text:
HIV
From Wikipedia, the free encyclopedia
Jump to: navigation, search
This article is about the virus. For the infection caused by the virus, see HIV/AIDS. For other uses, see HIV (disambiguation).
"AIDS virus" redirects here. For the computer virus, see AIDS (computer virus).
Human immunodeficiency virus
Scanning electron micrograph of HIV-1 (in green) budding from cultured lymphocyte. Multiple round bumps on cell surface represent sites of assembly and budding of virions.
Virus classification
Group: Group VI (ssRNA-RT)
Order: Unassigned
Family: Retroviridae
Subfamily: Orthoretrovirinae
Genus: Lentivirus
Species
Human immunodeficiency virus 1
Human immunodeficiency virus 2
The human immunodeficiency virus (HIV) is a lentivirus (a subgroup of retrovirus) that causes HIV infection and over time acquired immunodeficiency syndrome (AIDS).[1][2] AIDS is a condition in humans in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive. Without treatment, average survival time after infection with HIV is estimated to be 9 to 11 years, depending on the HIV subtype.[3] In most cases, HIV is a sexually transmitted infection and occurs by contact with or transfer of blood, pre-ejaculate, semen, and vaginal fluids. Non-sexual transmission can occur from an infected mother to her infant through breast milk.[4][5][6] An HIV-positive mother can transmit HIV to her baby both during pregnancy and childbirth due to exposure to her blood or vaginal fluid.[7] Within these bodily fluids, HIV is present as both free virus particles and virus within infected immune cells.
HIV infects vital cells in the human immune system such as helper T cells (specifically CD4+ T cells), macrophages, and dendritic cells.[8] HIV infection leads to low levels of CD4+ T cells through a number of mechanisms, including pyroptosis of abortively infected T cells,[9] apoptosis of uninfected bystander cells,[10] direct viral killing of infected cells, and killing of infected CD4+ T cells by CD8+ cytotoxic lymphocytes that recognize infected cells.[11] When CD4+ T cell numbers decline below a critical level, cell-mediated immunity is lost, and the body becomes progressively more susceptible to opportunistic infections, leading to the development of AIDS.
Contents
[hide]
1 Virology
1.1 Classification
1.2 Structure and genome
1.3 Tropism
1.4 Replication cycle
1.4.1 Entry to the cell
1.4.2 Replication and transcription
1.4.3 Recombination
1.4.4 Assembly and release
1.5 Spread within the body
1.6 Genetic variability
2 Diagnosis
3 Research
4 Treatment
5 History
5.1 Discovery
5.2 Origins
6 See also
7 References
8 Further reading
9 External links
Virology
Classification
See also: Subtypes of HIV
Comparison of HIV species
Species
Virulence
Infectivity
Prevalence
Inferred origin
HIV-1
High High Global Common chimpanzee
HIV-2
Lower Low West Africa Sooty mangabey
HIV is a member of the genus Lentivirus,[12] part of the family Retroviridae.[13] Lentiviruses have many morphologies and biological properties in common. Many species are infected by lentiviruses, which are characteristically responsible for long-duration illnesses with a long incubation period.[14] Lentiviruses are transmitted as single-stranded, positive-sense, enveloped RNA viruses. Upon entry into the target cell, the viral RNA genome is converted (reverse transcribed) into double-stranded DNA by a virally encoded enzyme, reverse transcriptase, that is transported along with the viral genome in the virus particle. The resulting viral DNA is then imported into the cell nucleus and integrated into the cellular DNA by a virally encoded enzyme, integrase, and host co-factors.[15] Once integrated, the virus may become latent, allowing the virus and its host cell to avoid detection by the immune system, for an indiscriminate amount of time.[16] The HIV virus can remain dormant in the human body for up to ten years after primary infection; during this period the virus does not cause symptoms. Alternatively, the integrated viral DNA may be transcribed, producing new RNA genomes and viral proteins, using host cell resources, that are packaged and released from the cell as new virus particles that will begin the replication cycle anew.
Two types of HIV have been characterized: HIV-1 and HIV-2. HIV-1 is the virus that was initially discovered and termed both LAV (Lymphadenopathy Associated Virus) and HTLV-III (Human T cell Lymphotropic Virus III). HIV-1 is more virulent and more infective than HIV-2,[17] and is the cause of the majority of HIV infections globally. The lower infectivity of HIV-2 compared to HIV-1 implies that fewer of those exposed to HIV-2 will be infected per exposure. Due to its relatively poor capacity for transmission, HIV-2 is largely confined to West Africa.[18]
Structure and genome
Main article: Structure and genome of HIV
Diagram of the HIV virion
HIV is different in structure from other retroviruses. It is roughly spherical[19] with a diameter of about 120 nm, around 60 times smaller than a red blood cell.[20] It is composed of two copies of positive-sense single-stranded RNA that codes for the virus's nine genes enclosed by a conical capsid composed of 2,000 copies of the viral protein p24.[21] The single-stranded RNA is tightly bound to nucleocapsid proteins, p7, and enzymes needed for the development of the virion such as reverse transcriptase, proteases, ribonuclease and integrase. A matrix composed of the viral protein p17 surrounds the capsid ensuring the integrity of the virion particle.[21]
This is, in turn, surrounded by the viral envelope, that is composed of the lipid bilayer taken from the membrane of a human host cell when the newly formed virus particle buds from the cell. The viral envelope contains proteins from the host cell and relatively few copies of the HIV Envelope protein,[21] which consists of a cap made of three molecules known as glycoprotein (gp) 120, and a stem consisting of three gp41 molecules that anchor the structure into the viral envelope.[22][23] The Envelope protein, encoded by the HIV env gene, allows the virus to attach to target cells and fuse the viral envelope with the target cell's membrane releasing the viral contents into the cell and initiating the infectious cycle.[22]
As the sole viral protein on the surface of the virus, the Envelope protein is a major target for HIV vaccine efforts.[24] Over half of the mass of the trimeric envelope spike is N-linked glycans. The density is high as the glycans shield the underlying viral protein from neutralisation by antibodies. This is one of the most densely glycosylated molecules known and the density is sufficiently high to prevent the normal maturation process of glycans during biogenesis in the endoplasmic and Golgi apparatus.[25][26] The majority of the glycans are therefore stalled as immature 'high-mannose' glycans not normally present on human glycoproteins that are secreted or present on a cell surface.[27] The unusual processing and high density means that almost all broadly neutralising antibodies that have so far been identified (from a subset of patients that have been infected for many months to years) bind to or, are adapted to cope with, these envelope glycans.[28]
The molecular structure of the viral spike has now been determined by X-ray crystallography[29] and cryo-electron microscopy.[30] These advances in structural biology were made possible due to the development of stable recombinant forms of the viral spike by the introduction of an intersubunit disulphide bond and an isoleucine to proline mutation in gp41.[31] The so-called SOSIP trimers not only reproduce the antigenic properties of the native viral spike but also display the same degree of immature glycans as presented on the native virus.[32] Recombinant trimeric viral spikes are promising vaccine candidates as they display less non-neutralising epitopes than recombinant monomeric gp120, which act to suppress the immune response to target epitopes.[33]
Structure of the RNA genome of HIV-1
The RNA genome consists of at least seven structural landmarks (LTR, TAR, RRE, PE, SLIP, CRS, and INS), and nine genes (gag, pol, and env, tat, rev, nef, vif, vpr, vpu, and sometimes a tenth tev, which is a fusion of tat, env and rev), encoding 19 proteins. Three of these genes, gag, pol, and env, contain information needed to make the structural proteins for new virus particles.[21] For example, env codes for a protein called gp160 that is cut in two by a cellular protease to form gp120 and gp41. The six remaining genes, tat, rev, nef, vif, vpr, and vpu (or vpx in the case of HIV-2), are regulatory genes for proteins that control the ability of HIV to infect cells, produce new copies of virus (replicate), or cause disease.[21]
The two Tat proteins (p16 and p14) are transcriptional transactivators for the LTR promoter acting by binding the TAR RNA element. The TAR may also be processed into microRNAs that regulate the apoptosis genes ERCC1 and IER3.[34][35] The Rev protein (p19) is involved in shuttling RNAs from the nucleus and the cytoplasm by binding to the RRE RNA element. The Vif protein (p23) prevents the action of APOBEC3G (a cellular protein that deaminates Cytidine to Uridine in the single stranded viral DNA and/or interferes with reverse transcription[36]). The Vpr protein (p14) arrests cell division at G2/M. The Nef protein (p27) down-regulates CD4 (the major viral receptor), as well as the MHC class I and class II molecules.[37][38][39]
Nef also interacts with SH3 domains. The Vpu protein (p16) influences the release of new virus particles from infected cells.[21] The ends of each strand of HIV RNA contain an RNA sequence called the long terminal repeat (LTR). Regions in the LTR act as switches to control production of new viruses and can be triggered by proteins from either HIV or the host cell. The Psi element is involved in viral genome packaging and recognized by Gag and Rev proteins. The SLIP element (TTTTTT) is involved in the frameshift in the Gag-Pol reading frame required to make functional Pol.[21]
Tropism
Main article: HIV tropism
Diagram of the immature and mature forms of HIV
The term viral tropism refers to the cell types a virus infects. HIV can infect a variety of immune cells such as CD4+ T cells, macrophages, and microglial cells. HIV-1 entry to macrophages and CD4+ T cells is mediated through interaction of the virion envelope glycoproteins (gp120) with the CD4 molecule on the target cells' membrane and also with chemokine co-receptors.[22][40]
Macrophage-tropic (M-tropic) strains of HIV-1, or non-syncytia-inducing strains (NSI; now called R5 viruses[41]) use the β-chemokine receptor CCR5 for entry and are, thus, able to replicate in both macrophages and CD4+ T cells.[42] This CCR5 co-receptor is used by almost all primary HIV-1 isolates regardless of viral genetic subtype. Indeed, macrophages play a key role in several critical aspects of HIV infection. They appear to be the first cells infected by HIV and perhaps the source of HIV production when CD4+ cells become depleted in the patient. Macrophages and microglial cells are the cells infected by HIV in the central nervous system. In tonsils and adenoids of HIV-infected patients, macrophages fuse into multinucleated giant cells that produce huge amounts of virus.
T-tropic strains of HIV-1, or syncytia-inducing (SI; now called X4 viruses[41]) strains replicate in primary CD4+ T cells as well as in macrophages and use the α-chemokine receptor, CXCR4, for entry.[42][43][44]
Dual-tropic HIV-1 strains are thought to be transitional strains of HIV-1 and thus are able to use both CCR5 and CXCR4 as co-receptors for viral entry.
The α-chemokine SDF-1, a ligand for CXCR4, suppresses replication of T-tropic HIV-1 isolates. It does this by down-regulating the expression of CXCR4 on the surface of HIV target cells. M-tropic HIV-1 isolates that use only the CCR5 receptor are termed R5; those that use only CXCR4 are termed X4, and those that use both, X4R5. However, the use of co-receptor alone does not explain viral tropism, as not all R5 viruses are able to use CCR5 on macrophages for a productive infection[42] and HIV can also infect a subtype of myeloid dendritic cells,[45] which probably constitute a reservoir that maintains infection when CD4+ T cell numbers have declined to extremely low levels.
Some people are resistant to certain strains of HIV.[46] For example, people with the CCR5-Δ32 mutation are resistant to infection by the R5 virus, as the mutation leaves HIV unable to bind to this co-receptor, reducing its ability to infect target cells.
Sexual intercourse is the major mode of HIV transmission. Both X4 and R5 HIV are present in the seminal fluid, which enables the virus to be transmitte from a male to his sexual partner. The virions can then infect numerous cellular targets and disseminate into the whole organism. However, a selection process leads to a predominant transmission of the R5 virus through this pathway.[47][48][49] In patients infected with subtype B HIV-1, there is often a co-receptor switch in late-stage disease and T-tropic variants that can infect a variety of T cells through CXCR4.[50] These variants then replicate more aggressively with heightened virulence that causes rapid T cell depletion, immune system collapse, and opportunistic infections that mark the advent of AIDS.[51] Thus, during the course of infection, viral adaptation to the use of CXCR4 instead of CCR5 may be a key step in the progression to AIDS. A number of studies with subtype B-infected individuals have determined that between 40 and 50 percent of AIDS patients can harbour viruses of the SI and, it is presumed, the X4 phenotypes.[52][53]
HIV-2 is much less pathogenic than HIV-1 and is restricted in its worldwide distribution to West Africa. The adoption of "accessory genes" by HIV-2 and its more promiscuous pattern of co-receptor usage (including CD4-independence) may assist the virus in its adaptation to avoid innate restriction factors present in host cells. Adaptation to use normal cellular machinery to enable transmission and productive infection has also aided the establishment of HIV-2 replication in humans. A survival strategy for any infectious agent is not to kill its host but ultimately become a commensal organism. Having achieved a low pathogenicity, over time, variants that are more successful at transmission will be selected.[54]
Replication cycle
The HIV replication cycle
Entry to the cell
Mechanism of viral entry: 1. Initial interaction between gp120 and CD4. 2. Conformational change in gp120 allows for secondary interaction with CCR5. 3. The distal tips of gp41 are inserted into the cellular membrane. 4. gp41 undergoes significant conformational change; folding in half and forming coiled-coils. This process pulls the viral and cellular membranes together, fusing them.
The HIV virion enters macrophages and CD4+ T cells by the adsorption of glycoproteins on its surface to receptors on the target cell followed by fusion of the viral envelope with the target cell membrane and the release of the HIV capsid into the cell.[55][56]
Entry to the cell begins through interaction of the trimeric envelope complex (gp160 spike) on the HIV viral envelope and both CD4 and a chemokine co-receptor (generally either CCR5 or CXCR4, but others are known to interact) on the target cell surface.[55][56] Gp120 binds to integrin α4β7 activating LFA-1, the central integrin involved in the establishment of virological synapses, which facilitate efficient cell-to-cell spreading of HIV-1.[57] The gp160 spike contains binding domains for both CD4 and chemokine receptors.[55][56]
The first step in fusion involves the high-affinity attachment of the CD4 binding domains of gp120 to CD4. Once gp120 is bound with the CD4 protein, the envelope complex undergoes a structural change, exposing the chemokine receptor binding domains of gp120 and allowing them to interact with the target chemokine receptor.[55][56] This allows for a more stable two-pronged attachment, which allows the N-terminal fusion peptide gp41 to penetrate the cell membrane.[55][56] Repeat sequences in gp41, HR1, and HR2 then interact, causing the collapse of the extracellular portion of gp41 into a hairpin. This loop structure brings the virus and cell membranes close together, allowing fusion of the membranes and subsequent entry of the viral capsid.[55][56]
After HIV has bound to the target cell, the HIV RNA and various enzymes, including reverse transcriptase, integrase, ribonuclease, and protease, are injected into the cell.[55][not in citation given] During the microtubule-based transport to the nucleus, the viral single-strand RNA genome is transcribed into double-strand DNA, which is then integrated into a host chromosome.
HIV can infect dendritic cells (DCs) by this CD4-CCR5 route, but another route using mannose-specific C-type lectin receptors such as DC-SIGN can also be used.[58] DCs are one of the first cells encountered by the virus during sexual transmission. They are currently thought to play an important role by transmitting HIV to T-cells when the virus is captured in the mucosa by DCs.[58] The presence of FEZ-1, which occurs naturally in neurons, is believed to prevent the infection of cells by HIV.[59]
Clathrin-dependent endocytosis
HIV-1 entry, as well as entry of many other retroviruses, has long been believed to occur exclusively at the plasma membrane. More recently, however, productive infection by pH-independent, clathrin-dependent endocytosis of HIV-1 has also been reported and was recently suggested to constitute the only route of productive entry.[60][61][62][63][64]
Replication and transcription
Reverse transcription of the HIV genome into double-stranded DNA
Shortly after the viral capsid enters the cell, an enzyme called reverse transcriptase liberates the positive-sense single-stranded RNA genome from the attached viral proteins and copies it into a complementary DNA (cDNA) molecule.[65] The process of reverse transcription is extremely error-prone, and the resulting mutations may cause drug resistance or allow the virus to evade the body's immune system. The reverse transcriptase also has ribonuclease activity that degrades the viral RNA during the synthesis of cDNA, as well as DNA-dependent DNA polymerase activity that creates a sense DNA from the antisense cDNA.[66] Together, the cDNA and its complement form a double-stranded viral DNA that is then transported into the cell nucleus. The integration of the viral DNA into the host cell's genome is carried out by another viral enzyme called integrase.[65]
The integrated viral DNA may then lie dormant, in the latent stage of HIV infection.[65] To actively produce the virus, certain cellular transcription factors need to be present, the most important of which is NF-κB (nuclear factor kappa B), which is upregulated when T cells become activated.[67] This means that those cells most likely to be targeted, entered and subsequently killed by HIV are those currently fighting infection.
During viral replication, the integrated DNA provirus is transcribed into RNA, some of which then undergo RNA splicing to produce mature mRNAs. These mRNAs are exported from the nucleus into the cytoplasm, where they are translated into the regulatory proteins Tat (which encourages new virus production) and Rev. As the newly produced Rev protein is produced it moves to the nucleus, where it binds to full-length, unspliced copies of virus RNAs and allows them to leave the nucleus.[68] Some of these full-length RNAs function as new copies of the virus genome, while others function as mRNAs that are translated to produce the structural proteins Gag and Env. Gag proteins bind to copies of the virus RNA genome to package them into new virus particles.[69]
HIV-1 and HIV-2 appear to package their RNA differently.[70][citation needed] HIV-1 will bind to any appropriate RNA.[citation needed] HIV-2 will preferentially bind to the mRNA that was used to create the Gag protein itself.[71]
Recombination
Two RNA genomes are encapsidated in each HIV-1 particle (see Structure and genome of HIV). Upon infection and replication catalyzed by reverse transcriptase, recombination between the two genomes can occur.[72][73] Recombination occurs as the single-strand (+)RNA genomes are reverse transcribed to form DNA. During reverse transcription, the nascent DNA can switch multiple times between the two copies of the viral RNA. This form of recombination is known as copy-choice. Recombination events may occur throughout the genome. Anywhere from two to 20 recombination events per genome may occur at each replication cycle, and these events can rapidly shuffle the genetic information that is transmitted from parental to progeny genomes.[73]
Viral recombination produces genetic variation that likely contributes to the evolution of resistance to anti-retroviral therapy.[74] Recombination may also contribute, in principle, to overcoming the immune defenses of the host. Yet, for the adaptive advantages of genetic variation to be realized, the two viral genomes packaged in individual infecting virus particles need to have arisen from separate progenitor parental viruses of differing genetic constitution. It is unknown how often such mixed packaging occurs under natural conditions.[75]
Bonhoeffer et al.[76] suggested that template switching by reverse transcriptase acts as a repair process to deal with breaks in the single-stranded RNA genome. In addition, Hu and Temin[72] suggested that recombination is an adaptation for repair of damage in the RNA genomes. Strand switching (copy-choice recombination) by reverse transcriptase could generate an undamaged copy of genomic DNA from two damaged single-stranded RNA genome copies. This view of the adaptive benefit of recombination in HIV could explain why each HIV particle contains two complete genomes, rather than one. Furthermore, the view that recombination is a repair process implies that the benefit of repair can occur at each replication cycle, and that this benefit can be realized whether or not the two genomes differ genetically. On the view that recombination in HIV is a repair process, the generation of recombinational variation would be a consequence, but not the cause of, the evolution of template switching.[76]
HIV-1 infection causes chronic ongoing inflammation and production of reactive oxygen species.[77] Thus, the HIV genome may be vulnerable to oxidative damages, including breaks in the single-stranded RNA. For HIV, as well as for viruses generally, successful infection depends on overcoming host defensive strategies that often include production of genome-damaging reactive oxygen. Thus, Michod et al.[78] suggested that recombination by viruses is an adaptation for repair of genome damages, and that recombinational variation is a byproduct that may provide a separate benefit.
Assembly and release
HIV assembling on the surface of an infected macrophage. The HIV virions have been marked with a green fluorescent tag and then viewed under a fluorescent microscope.
The final step of the viral cycle, assembly of new HIV-1 virions, begins at the plasma membrane of the host cell. The Env polyprotein (gp160) goes through the endoplasmic reticulum and is transported to the Golgi complex where it is cleaved by furin resulting in the two HIV envelope glycoproteins, gp41 and gp120.[79] These are transported to the plasma membrane of the host cell where gp41 anchors gp120 to the membrane of the infected cell. The Gag (p55) and Gag-Pol (p160) polyproteins also associate with the inner surface of the plasma membrane along with the HIV genomic RNA as the forming virion begins to bud from the host cell. The budded virion is still immature as the gag polyproteins still need to be cleaved into the actual matrix, capsid and nucleocapsid proteins. This cleavage is mediated by the packaged viral protease and can be inhibited by antiretroviral drugs of the protease inhibitor class. The various structural components then assemble to produce a mature HIV virion.[80] Only mature virions are then able to infect another cell.
Spread within the body
Animation demonstrating cell-free spread of HIV.
The classical process of infection of a cell by a virion can be called "cell-free spread" to distinguish it from a more recently-recognized process called "cell-to-cell spread".[81] In cell-free spread (see figure), virus particles bud from an infected T cell, enter the blood or extracellular fluid and then infect another T cell following a chance encounter.[81] HIV can also disseminate by direct transmission from one cell to another by a process of cell-to-cell spread, for which two pathways have been described. Firstly, an infected T cell can transmit virus directly to a target T cell via a virological synapse.[57][82] Secondly, an antigen-presenting cell (APC), such as a macrophage or dendritic cell, can transmit HIV to T cells by a process that either involves productive infection (in the case of macrophages) or capture and transfer of virions in trans (in the case of dendritic cells).[83] Whichever pathway is used, infection by cell-to-cell transfer is reported to be much more efficient than cell-free virus spread.[84] A number of factors contribute to this increased efficiency, including polarised virus budding towards the site of cell-to-cell contact, close apposition of cells, which minimizes fluid-phase diffusion of virions, and clustering of HIV entry receptors on the target cell to the contact zone.[82] Cell-to-cell spread is thought to be particularly important in lymphoid tissues where CD4+ T cells are densely packed and likely to interact frequently.[81] Intravital imaging studies have supported the concept of the HIV virological synapse in vivo.[85] The hybrid spreading mechanisms of HIV contribute to the virus' ongoing replication in spite of anti-retroviral therapies.[81][86]
Genetic variability
Further information: Subtypes of HIV
The phylogenetic tree of the SIV and HIV
HIV differs from many viruses in that it has very high genetic variability. This diversity is a result of its fast replication cycle, with the generation of about 1010 virions every day, coupled with a high mutation rate of approximately 3 x 10−5 per nucleotide base per cycle of replication and recombinogenic properties of reverse transcriptase.[87][88][89]
This complex scenario leads to the generation of many variants of HIV in a single infected patient in the course of one day.[87] This variability is compounded when a single cell is simultaneously infected by two or more different strains of HIV. When simultaneous infection occurs, the genome of progeny virions may be composed of RNA strands from two different strains. This hybrid virion then infects a new cell where it undergoes replication. As this happens, the reverse transcriptase, by jumping back and forth between the two different RNA templates, will generate a newly synthesized retroviral DNA sequence that is a recombinant between the two parental genomes.[87] This recombination is most obvious when it occurs between subtypes.[87]
The closely related simian immunodeficiency virus (SIV) has evolved into many strains, classified by the natural host species. SIV strains of the African green monkey (SIVagm) and sooty mangabey (SIVsmm) are thought to have a long evolutionary history with their hosts. These hosts have adapted to the presence of the virus,[90] which is present at high levels in the host's blood, but evokes only a mild immune response,[91] does not cause the development of simian AIDS,[92] and does not undergo the extensive mutation and recombination typical of HIV infection in humans.[93]
In contrast, when these strains infect species that have not adapted to SIV ("heterologous" or similar hosts such as rhesus or cynomologus macaques), the animals develop AIDS and the virus generates genetic diversity similar to what is seen in human HIV infection.[94] Chimpanzee SIV (SIVcpz), the closest genetic relative of HIV-1, is associated with increased mortality and AIDS-like symptoms in its natural host.[95] SIVcpz appears to have been transmitted relatively recently to chimpanzee and human populations, so their hosts have not yet adapted to the virus.[90] This virus has also lost a function of the Nef gene that is present in most SIVs. For non-pathogenic SIV variants, Nef suppresses T cell activation through the CD3 marker. Nef's function in non-pathogenic forms of SIV is to downregulate expression of inflammatory cytokines, MHC-1, and signals that affect T cell trafficking. In HIV-1 and SIVcpz, Nef does not inhibit T-cell activation and it has lost this function. Without this function, T cell depletion is more likely, leading to immunodeficiency.[95][96]
Three groups of HIV-1 have been identified on the basis of differences in the envelope (env) region: M, N, and O.[97] Group M is the most prevalent and is subdivided into eight subtypes (or clades), based on the whole genome, which are geographically distinct.[98] The most prevalent are subtypes B (found mainly in North America and Europe), A and D (found mainly in Africa), and C (found mainly in Africa and Asia); these subtypes form branches in the phylogenetic tree representing the lineage of the M group of HIV-1. Co-infection with distinct subtypes gives rise to circulating recombinant forms (CRFs). In 2000, the last year in which an analysis of global subtype prevalence was made, 47.2% of infections worldwide were of subtype C, 26.7% were of subtype A/CRF02_AG, 12.3% were of subtype B, 5.3% were of subtype D, 3.2% were of CRF_AE, and the remaining 5.3% were composed of other subtypes and CRFs.[99] Most HIV-1 research is focused on subtype B; few laboratories focus on the other subtypes.[100] The existence of a fourth group, "P", has been hypothesised based on a virus isolated in 2009.[101] The strain is apparently derived from gorilla SIV (SIVgor), first isolated from western lowland gorillas in 2006.[101]
HIV-2's closest relative is SIVsm, a strain of SIV found in sooty mangabees. Since HIV-1 is derived from SIVcpz, and HIV-2 from SIVsm, the genetic sequence of HIV-2 is only partially homologous to HIV-1 and more closely resembles that of SIVsm.[citation needed][102]
Diagnosis
Main article: Diagnosis of HIV/AIDS
A generalized graph of the relationship between HIV copies (viral load) and CD4 counts over the average course of untreated HIV infection; any particular individual's disease course may vary considerably.
CD4+ T cell count (cells per µL)
HIV RNA copies per mL of plasma
Many HIV-positive people are unaware that they are infected with the virus.[103] For example, in 2001 less than 1% of the sexually active urban population in Africa had been tested, and this proportion is even lower in rural populations.[103] Furthermore, in 2001 only 0.5% of pregnant women attending urban health facilities were counselled, tested or receive their test results.[103] Again, this proportion is even lower in rural health facilities.[103] Since donors may therefore be unaware of their infection, donor blood and blood products used in medicine and medical research are routinely screened for HIV.[104]
HIV-1 testing is initially done using an enzyme-linked immunosorbent assay (ELISA) to detect antibodies to HIV-1. Specimens with a non-reactive result from the initial ELISA are considered HIV-negative unless new exposure to an infected partner or partner of unknown HIV status has occurred. Specimens with a reactive ELISA result are retested in duplicate.[105] If the result of either duplicate test is reactive, the specimen is reported as repeatedly reactive and undergoes confirmatory testing with a more specific supplemental test (e.g., a polymerase chain reaction (PCR), western blot or, less commonly, an immunofluorescence assay (IFA)). Only specimens that are repeatedly reactive by ELISA and positive by IFA or PCR or reactive by western blot are considered HIV-positive and indicative of HIV infection. Specimens that are repeatedly ELISA-reactive occasionally provide an indeterminate western blot result, which may be either an incomplete antibody response to HIV in an infected person or nonspecific reactions in an uninfected person.[106]
HIV deaths (other than U.S.) in 2014.[107]
Nigeria (15.76%)
South Africa (12.51%)
India (11.50%)
Tanzania (4.169%)
Mozambique (4.061%)
Zimbabwe (3.49%)
Cameroon (3.09%)
Indonesia (3.04%)
Kenya (2.98%)
Uganda (2.97%)
Malawi (2.94%)
DR Congo (2.17%)
Ethiopia (2.11%)
Other (29.21%)
Although IFA can be used to confirm infection in these ambiguous cases, this assay is not widely used. In general, a second specimen should be collected more than a month later and retested for persons with indeterminate western blot results. Although much less commonly available, nucleic acid testing (e.g., viral RNA or proviral DNA amplification method) can also help diagnosis in certain situations.[105] In addition, a few tested specimens might provide inconclusive results because of a low quantity specimen. In these situations, a second specimen is collected and tested for HIV infection.
Modern HIV testing is extremely accurate. A single screening test is correct more than 99% of the time.[108][needs update] The chance of a false-positive result in standard two-step testing protocol is estimated to be about 1 in 250,000 in a low risk population.[108] Testing post-exposure is recommended immediately and then at six weeks, three months, and six months.[109]
The latest recommendations of the CDC show that HIV testing must start with an immunoassay combination test for HIV-1 and HIV-2 antibodies and p24 antigen. A negative result rules out HIV exposure, while a positive one must be followed by an HIV-1/2 antibody differentiation immunoassay to detect which antibodies are present. This gives rise to four possible scenarios:
1. HIV-1 (+) & HIV-2 (−): HIV-1 antibodies detected
2. HIV-1 (−) & HIV-2 (+): HIV-2 antibodies detected
3. HIV-1 (+) & HIV-2 (+): both HIV-1 and HIV-2 antibodies detected
4. HIV-1 (−) or indeterminate & HIV-2 (−): Nucleic acid test must be carried out to detect the acute infection of HIV-1 or its absence.[110]
An updated algorithm published by the CDC in June 2014 recommends that diagnosis starts with the p24 antigen test. A negative result rules out infection, while a positive one must be followed by an HIV-1/2 antibody differentiation immunoassay. A positive differentiation test confirms diagnosis, while a negative or indeterminate result must be followed by nucleic acid test (NAT). A positive NAT result confirms HIV-1 infection whereas a negative result rules out infection (false positive p24).[111]
Research
Main article: HIV/AIDS research
HIV/AIDS research includes all medical research that attempts to prevent, treat, or cure HIV/AIDS, as well as fundamental research about the nature of HIV as an infectious agent and AIDS as the disease caused by HIV.
Many governments and research institutions participate in HIV/AIDS research. This research includes behavioral health interventions, such as research into sex education, and drug development, such as research into microbicides for sexually transmitted diseases, HIV vaccines, and anti-retroviral drugs.[112] Other medical research areas include the topics of pre-exposure prophylaxis, post-exposure prophylaxis, circumcision and HIV, and accelerated aging effects.
After many years of research, an untested HIV vaccine has been created.[113] Bi-specific antibodies, that target both the surface of T-cells and viral epitopes, can prevent entry of the virus into human cells.[114] Another group has utilised the same technology to develop a bi-specific antibody that neutralises viral particles by cross-linking of envelope glycoproteins.[115]
Treatment
Main article: Management of HIV/AIDS
HIV latency, and the consequent viral reservoir in CD4+ T cells, dendritic cells, as well as macrophages, is the main barrier to eradication of the virus.[16]
It is important to note that although HIV is highly virulent, transmission is greatly reduced when an HIV-infected person has a suppressed or undetectable viral load (<50 copies/ml) due to prolonged and successful anti-retroviral treatment. Hence, it can be said to be almost impossible (but still non-zero) for an HIV-infected person who has an undetectable viral load to transmit the virus, even during unprotected sexual intercourse, as there would be a negligible amount of HIV present in the seminal fluid, vaginal secretions or blood, for transmission to occur.[116][117] This does not mean however, that prolonged anti-retroviral treatment will result in a suppressed viral load. An undetectable viral load, generally agreed as less than 50 copies per milliliter of blood, can only be proven by a polymerase chain reaction (PCR) test.[118]
At the same time, it is important to recognise that reaching an undetectable viral load is determined by many factors, including treatment adherence, HIV resistance to certain anti-retroviral drugs, stigma, and inadequate health systems.[119]
History
Main article: History of HIV/AIDS
Discovery
AIDS was first clinically observed in 1981 in the United States.[120] The initial cases were a cluster of injection drug users and gay men with no known cause of impaired immunity who showed symptoms of Pneumocystis carinii pneumonia (PCP), a rare opportunistic infection that was known to occur in people with very compromised immune systems.[121] Soon thereafter, additional gay men developed a previously rare skin cancer called Kaposi's sarcoma (KS).[122][123] Many more cases of PCP and KS emerged, alerting U.S. Centers for Disease Control and Prevention (CDC) and a CDC task force was formed to monitor the outbreak.[124] The earliest retrospectively described case of AIDS is believed to have been in Norway beginning in 1966.[125]
In the beginning, the CDC did not have an official name for the disease, often referring to it by way of the diseases that were associated with it, for example, lymphadenopathy, the disease after which the discoverers of HIV originally named the virus.[126][127] They also used Kaposi's Sarcoma and Opportunistic Infections, the name by which a task force had been set up in 1981.[128] In the general press, the term GRID, which stood for gay-related immune deficiency, had been coined.[129] The CDC, in search of a name, and looking at the infected communities coined "the 4H disease", as it seemed to single out homosexuals, heroin users, hemophiliacs, and Haitians.[130][131] However, after determining that AIDS was not isolated to the gay community,[128] it was realized that the term GRID was misleading and AIDS was introduced at a meeting in July 1982.[132] By September 1982 the CDC started using the name AIDS.[133]
Françoise Barré-Sinoussi, co-discoverer of HIV
In 1983, two separate research groups led by American Robert Gallo and French investigators Françoise Barré-Sinoussi and Luc Montagnier independently declared that a novel retrovirus may have been infecting AIDS patients, and published their findings in the same issue of the journal Science.[134][135][136] Gallo claimed that a virus his group had isolated from a person with AIDS was strikingly similar in shape to other human T-lymphotropic viruses (HTLVs) his group had been the first to isolate. Gallo's group called their newly isolated virus HTLV-III. At the same time, Montagnier's group isolated a virus from a patient presenting with swelling of the lymph nodes of the neck and physical weakness, two classic symptoms of AIDS. Contradicting the report from Gallo's group, Montagnier and his colleagues showed that core proteins of this virus were immunologically different from those of HTLV-I. Montagnier's group named their isolated virus lymphadenopathy-associated virus (LAV).[124] As these two viruses turned out to be the same, in 1986 LAV and HTLV-III were renamed HIV.[137]
Another group working contemporaneously with the Montagnier and Gallo groups was that of Dr. Jay Levy at the University of California, San Francisco. He independently discovered the AIDS virus in 1983 and named it the AIDS associated retrovirus (ARV).[138] This virus was very different from the virus reported by the Montagnier and Gallo groups. The ARV strains indicated, for the first time, the heterogeneity of HIV isolates and several of these remain classic examples of the AIDS virus found in the United States.[139]
Origins
Both HIV-1 and HIV-2 are believed to have originated in non-human primates in West-central Africa, and are believed to have transferred to humans (a process known as zoonosis) in the early 20th century.[140][141]
HIV-1 appears to have originated in southern Cameroon through the evolution of SIV(cpz), a simian immunodeficiency virus (SIV) that infects wild chimpanzees (HIV-1 descends from the SIV(cpz) endemic in the chimpanzee subspecies Pan troglodytes troglodytes).[142][143] The closest relative of HIV-2 is SIV (smm), a virus of the sooty mangabey (Cercocebus atys atys), an Old World monkey living in littoral West Africa (from southern Senegal to western Côte d'Ivoire).[18] New World monkeys such as the owl monkey are resistant to HIV-1 infection, possibly because of a genomic fusion of two viral resistance genes.[144] HIV-1 is thought to have jumped the species barrier on at least three separate occasions, giving rise to the three groups of the virus, M, N, and O.[145]
Left to right: the African green monkey source of SIV, the sooty mangabey source of HIV-2, and the chimpanzee source of HIV-1
There is evidence that humans who participate in bushmeat activities, either as hunters or as bushmeat vendors, commonly acquire SIV.[146] However, SIV is a weak virus, and it is typically suppressed by the human immune system within weeks of infection. It is thought that several transmissions of the virus from individual to individual in quick succession are necessary to allow it enough time to mutate into HIV.[147] Furthermore, due to its relatively low person-to-person transmission rate, it can only spread throughout the population in the presence of one or more high-risk transmission channels, which are thought to have been absent in Africa prior to the 20th century.
Specific proposed high-risk transmission channels, allowing the virus to adapt to humans and spread throughout the society, depend on the proposed timing of the animal-to-human crossing. Genetic studies of the virus suggest that the most recent common ancestor of the HIV-1 M group dates back to circa 1910.[148] Proponents of this dating link the HIV epidemic with the emergence of colonialism and growth of large colonial African cities, leading to social changes, including different patterns of sexual contact (especially multiple, concurrent partnerships), the spread of prostitution, and the concomitant high frequency of genital ulcer diseases (such as syphilis) in nascent colonial cities.[149] While transmission rates of HIV during vaginal intercourse are typically low, they are increased many fold if one of the partners suffers from a sexually transmitted infection resulting in genital ulcers. Early 1900s colonial cities were notable due to their high prevalence of prostitution and genital ulcers to the degree that as of 1928 as many as 45% of female residents of eastern Leopoldville were thought to have been prostitutes and as of 1933 around 15% of all residents of the same city were infected by one of the forms of syphilis.[149]
An alternative view — unsupported by evidence — holds that unsafe medical practices in Africa during years following World War II, such as unsterile reuse of single-use syringes during mass vaccination, antibiotic, and anti-malaria treatment campaigns, were the initial vector that allowed the virus to adapt to humans and spread.[147][150][151]
The earliest, well-documented case of HIV in a human dates back to 1959 in the Belgian Congo.[152] The virus may have been present in the United States as early as the mid-to-late 1950s, as a sixteen-year-old male presented with symptoms in 1966 died in 1969.[153]
See also
Medicine portal
Viruses portal
Antiviral drug
Discovery and development of HIV-protease inhibitors
HIV/AIDS denialism
World AIDS Day
References
Jump up ^ Weiss RA (May 1993). "How does HIV cause AIDS?". Science. 260 (5112): 1273–9. Bibcode:1993Sci...260.1273W. doi:10.1126/science.8493571. PMID 8493571.
Jump up ^ Douek DC, Roederer M, Koup RA (2009). "Emerging Concepts in the Immunopathogenesis of AIDS". Annual Review of Medicine. 60: 471–84. doi:10.1146/annurev.med.60.041807.123549. PMC 2716400  . PMID 18947296.
Jump up ^ UNAIDS, WHO (December 2007). "2007 AIDS epidemic update" (PDF). p. 10. Retrieved 2008-03-12.
Jump up ^ Mabuka J, Nduati R, Odem-Davis K, Peterson D, Overbaugh J (2012). Desrosiers RC, ed. "HIV-Specific Antibodies Capable of ADCC Are Common in Breastmilk and Are Associated with Reduced Risk of Transmission in Women with High Viral Loads". PLOS Pathogens. 8 (6): e1002739. doi:10.1371/journal.ppat.1002739. PMC 3375288  . PMID 22719248.
Jump up ^ Hahn, Robert A.; Inhorn, Marcia Claire, eds. (2009). Anthropology and public health : bridging differences in culture and society (2nd ed.). Oxford: Oxford University Press. p. 449. ISBN 978-0-19-537464-3. OCLC 192042314.
Jump up ^ Mead MN (2008). "Contaminants in human milk: weighing the risks against the benefits of breastfeeding". Environmental Health Perspectives. 116 (10): A426–34. doi:10.1289/ehp.116-a426. PMC 2569122  . PMID 18941560. Archived from the original on 6 November 2008.
Jump up ^ "Preventing Mother-to-Child Transmission of HIV". HIV.gov. Retrieved 2017-12-08. This article incorporates text from this source, which is in the public domain.
Jump up ^ Cunningham AL, Donaghy H, Harman AN, Kim M, Turville SG (2010). "Manipulation of dendritic cell function by viruses". Current Opinion in Microbiology. 13 (4): 524–529. doi:10.1016/j.mib.2010.06.002. PMID 20598938.
Jump up ^ Doitsh, Gilad; Galloway, Nicole L. K.; Geng, Xin; Yang, Zhiyuan; Monroe, Kathryn M.; Zepeda, Orlando; Hunt, Peter W.; Hatano, Hiroyu; Sowinski, Stefanie; Muñoz-Arias, Isa; Greene, Warner C. (2014). "Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection". Nature. 505 (7484): 509–514. doi:10.1038/nature12940. PMC 4047036  . PMID 24356306.
Jump up ^ Garg H, Mohl J, Joshi A (Nov 9, 2012). "HIV-1 induced bystander apoptosis". Viruses. 4 (11): 3020–43. doi:10.3390/v4113020. PMC 3509682  . PMID 23202514.
Jump up ^ Kumar, Vinay (2012). Robbins Basic Pathology (9th ed.). p. 147. ISBN 978-1-4557-3787-1.
Jump up ^ International Committee on Taxonomy of Viruses (2002). "61.0.6. Lentivirus". National Institutes of Health. Retrieved February 28, 2006.
Jump up ^ International Committee on Taxonomy of Viruses (2002). "61. Retroviridae". National Institutes of Health. Retrieved February 28, 2006.
Jump up ^ Levy JA (1993). "HIV pathogenesis and long-term survival". AIDS. 7 (11): 1401–10. doi:10.1097/00002030-199311000-00001. PMID 8280406.
Jump up ^ Smith JA, Daniel R (2006). "Following the path of the virus: the exploitation of host DNA repair mechanisms by retroviruses". ACS Chemical Biology. 1 (4): 217–26. doi:10.1021/cb600131q. PMID 17163676.
^ Jump up to: a b HIV Latency (2011), https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234450/, accessed 14 December 2017, Cold Spring Harb Perspect Med, 1(1): a007096
Jump up ^ Gilbert PB, McKeague IW, Eisen G, Mullins C, Guéye-NDiaye A, Mboup S, Kanki PJ (February 28, 2003). "Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal". Statistics in Medicine. 22 (4): 573–593. doi:10.1002/sim.1342. PMID 12590415.
^ Jump up to: a b Reeves JD, Doms RW (2002). "Human Immunodeficiency Virus Type 2" (PDF). Journal of General Virology. 83 (Pt 6): 1253–65. doi:10.1099/0022-1317-83-6-1253. PMID 12029140.
Jump up ^ McGovern SL, Caselli E, Grigorieff N, Shoichet BK (2002). "A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening". Journal of Medicinal Chemistry. 45 (8): 1712–22. doi:10.1021/jm010533y. PMID 11931626.
Jump up ^ Compared with overview in: Fisher, Bruce; Harvey, Richard P.; Champe, Pamela C. (2007). Lippincott's Illustrated Reviews: Microbiology. Lippincott's Illustrated Reviews. Hagerstown, MD: Lippincott Williams & Wilkins. p. 3. ISBN 0-7817-8215-5.
^ Jump up to: a b c d e f g Various (2008). HIV Sequence Compendium 2008 Introduction (PDF). Retrieved March 31, 2009.
^ Jump up to: a b c Chan DC, Fass D, Berger JM, Kim PS (1997). "Core structure of gp41 from the HIV envelope glycoprotein" (PDF). Cell. 89 (2): 263–73. doi:10.1016/S0092-8674(00)80205-6. PMID 9108481.
Jump up ^ Klein, Joshua S.; Bjorkman, Pamela J.; Rall, Glenn F. (27 May 2010). "Few and Far Between: How HIV May Be Evading Antibody Avidity". PLOS Pathogens. 6 (5): e1000908. doi:10.1371/journal.ppat.1000908. PMC 2877745  . PMID 20523901.
Jump up ^ National Institute of Health (June 17, 1998). "Crystal structure of key HIV protein reveals new prevention, treatment targets" (Press release). Archived from the original on February 19, 2006. Retrieved September 14, 2006.
Jump up ^ Behrens, Anna-Janina; Vasiljevic, Snezana; Pritchard, Laura K; Harvey, David J; Andev, Rajinder S; Krumm, Stefanie A; Struwe, Weston B; Cupo, Albert; Kumar, Abhinav; Zitzmann, Nicole; Seabright, Gemma E; Kramer, Holger B; Spencer, Daniel I.R; Royle, Louise; Lee, Jeong Hyun; Klasse, Per J; Burton, Dennis R; Wilson, Ian A; Ward, Andrew B; Sanders, Rogier W; Moore, John P; Doores, Katie J; Crispin, Max (2016). "Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein". Cell Reports. 14 (11): 2695–706. doi:10.1016/j.celrep.2016.02.058. PMC 4805854  . PMID 26972002.
Jump up ^ Pritchard, Laura K; Spencer, Daniel I.R; Royle, Louise; Bonomelli, Camille; Seabright, Gemma E; Behrens, Anna-Janina; Kulp, Daniel W; Menis, Sergey; Krumm, Stefanie A; Dunlop, D. Cameron; Crispin, Daniel J; Bowden, Thomas A; Scanlan, Christopher N; Ward, Andrew B; Schief, William R; Doores, Katie J; Crispin, Max (2015). "Glycan clustering stabilizes the mannose patch of HIV-1 and preserves vulnerability to broadly neutralizing antibodies". Nature Communications. 6: 7479. Bibcode:2015NatCo...6E7479P. doi:10.1038/ncomms8479. PMC 4500839  . PMID 26105115.
Jump up ^ Pritchard, Laura K; Harvey, David J; Bonomelli, Camille; Crispin, Max; Doores, Katie J (2015). "Cell- and Protein-Directed Glycosylation of Native Cleaved HIV-1 Envelope". Journal of Virology. 89 (17): 8932–44. doi:10.1128/JVI.01190-15. PMC 4524065  . PMID 26085151.
Jump up ^ Crispin, Max; Doores, Katie J (2015). "Targeting host-derived glycans on enveloped viruses for antibody-based vaccine design". Current Opinion in Virology. 11: 63–9. doi:10.1016/j.coviro.2015.02.002. PMC 4827424  . PMID 25747313.
Jump up ^ Julien, Jean-Philippe; Cupo, Albert; Sok, Devin; Stanfield, Robyn L.; Lyumkis, Dmitry; Deller, Marc C.; Klasse, Per-Johan; Burton, Dennis R.; Sanders, Rogier W. (2013-12-20). "Crystal structure of a soluble cleaved HIV-1 envelope trimer". Science. 342 (6165): 1477–1483. doi:10.1126/science.1245625. ISSN 1095-9203. PMC 3886632  . PMID 24179159.
Jump up ^ Lyumkis, Dmitry; Julien, Jean-Philippe; de Val, Natalia; Cupo, Albert; Potter, Clinton S.; Klasse, Per-Johan; Burton, Dennis R.; Sanders, Rogier W.; Moore, John P. (2013-12-20). "Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer". Science. 342 (6165): 1484–1490. doi:10.1126/science.1245627. ISSN 1095-9203. PMC 3954647  . PMID 24179160.
Jump up ^ Sanders, Rogier W.; Derking, Ronald; Cupo, Albert; Julien, Jean-Philippe; Yasmeen, Anila; de Val, Natalia; Kim, Helen J.; Blattner, Claudia; de la Peña, Alba Torrents (2013-09-01). "A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies". PLOS Pathogens. 9 (9): e1003618. doi:10.1371/journal.ppat.1003618. ISSN 1553-7374. PMC 3777863  . PMID 24068931.
Jump up ^ Pritchard, Laura K.; Vasiljevic, Snezana; Ozorowski, Gabriel; Seabright, Gemma E.; Cupo, Albert; Ringe, Rajesh; Kim, Helen J.; Sanders, Rogier W.; Doores, Katie J. (2015-06-16). "Structural Constraints Determine the Glycosylation of HIV-1 Envelope Trimers". Cell Reports. 11 (10): 1604–1613. doi:10.1016/j.celrep.2015.05.017. ISSN 2211-1247. PMC 4555872  . PMID 26051934.
Jump up ^ de Taeye, Steven W.; Ozorowski, Gabriel; Torrents de la Peña, Alba; Guttman, Miklos; Julien, Jean-Philippe; van den Kerkhof, Tom L. G. M.; Burger, Judith A.; Pritchard, Laura K.; Pugach, Pavel (2015-12-17). "Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes". Cell. 163 (7): 1702–1715. doi:10.1016/j.cell.2015.11.056. ISSN 1097-4172. PMC 4732737  . PMID 26687358.
Jump up ^ Ouellet DL, Plante I, Landry P, Barat C, Janelle ME, Flamand L, Tremblay MJ, Provost P (April 2008). "Identification of functional microRNAs released through asymmetrical processing of HIV-1 TAR element". Nucleic Acids Research. 36 (7): 2353–65. doi:10.1093/nar/gkn076. PMC 2367715  . PMID 18299284.
Jump up ^ Klase Z, Winograd R, Davis J, Carpio L, Hildreth R, Heydarian M, Fu S, McCaffrey T, Meiri E, Ayash-Rashkovsky M, Gilad S, Bentwich Z, Kashanchi F (2009). "HIV-1 TAR miRNA protects against apoptosis by altering cellular gene expression". Retrovirology. 6 (1): 18. doi:10.1186/1742-4690-6-18. PMC 2654423  . PMID 19220914.
Jump up ^ Vasudevan AA, Smits SH, Höppner A, Häussinger D, Koenig BW, Münk C (Nov 2013). "Structural features of antiviral DNA cytidine deaminases". Biological Chemistry. 394 (11): 1357–70. doi:10.1515/hsz-2013-0165. PMID 23787464.
Jump up ^ Garcia JV, Miller AD (April 1991). "Serine phosphorylation-independent downregulation of cell-surface CD4 by nef". Nature. 350 (6318): 508–11. Bibcode:1991Natur.350..508G. doi:10.1038/350508a0. PMID 2014052.
Jump up ^ Schwartz O, Maréchal V, Le Gall S, Lemonnier F, Heard JM (March 1996). "Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein". Nature Medicine. 2 (3): 338–42. doi:10.1038/nm0396-338. PMID 8612235.
Jump up ^ Stumptner-Cuvelette P, Morchoisne S, Dugast M, Le Gall S, Raposo G, Schwartz O, Benaroch P (October 2001). "HIV-1 Nef impairs MHC class II antigen presentation and surface expression". Proceedings of the National Academy of Sciences of the United States of America. 98 (21): 12144–9. Bibcode:2001PNAS...9812144S. doi:10.1073/pnas.221256498. PMC 59782  . PMID 11593029.
Jump up ^ Arrildt, Kathryn Twigg; Joseph, Sarah Beth; Swanstrom, Ronald (March 2012). "The HIV-1 Env Protein: A Coat of Many Colors". Current HIV/AIDS Reports (Current HIV/AIDS Reports): 53–63.
^ Jump up to: a b Berger EA, Doms RW, Fenyö EM, Korber BT, Littman DR, Moore JP, Sattentau QJ, Schuitemaker H, Sodroski J, Weiss RA (1998). "A new classification for HIV-1". Nature. 391 (6664): 240. Bibcode:1998Natur.391..240B. doi:10.1038/34571. PMID 9440686.
^ Jump up to: a b c Coakley E, Petropoulos CJ, Whitcomb JM (2005). "Assessing ch vbgemokine co-receptor usage in HIV". Current Opinion in Infectious Diseases. 18 (1): 9–15. doi:10.1097/00001432-200502000-00003. PMID 15647694.
Jump up ^ Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, Landau NR (1996). "Identification of a major co-receptor for primary isolates of HIV-1". Nature. 381 (6584): 661–6. Bibcode:1996Natur.381..661D. doi:10.1038/381661a0. PMID 8649511.
Jump up ^ Feng Y, Broder CC, Kennedy PE, Berger EA (1996). "HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor". Science. 272 (5263): 872–7. Bibcode:1996Sci...272..872F. doi:10.1126/science.272.5263.872. PMID 8629022.
Jump up ^ Knight SC, Macatonia SE, Patterson S (1990). "HIV I infection of dendritic cells". International Review of Immunology. 6 (2–3): 163–75. doi:10.3109/08830189009056627. PMID 2152500.
Jump up ^ Tang J, Kaslow RA (2003). "The impact of host genetics on HIV infection and disease progression in the era of highly active antiretroviral therapy". AIDS. 17 (Suppl 4): S51–S60. doi:10.1097/00002030-200317004-00006. PMID 15080180.
Jump up ^ Zhu T, Mo H, Wang N, Nam DS, Cao Y, Koup RA, Ho DD (1993). "Genotypic and phenotypic characterization of HIV-1 patients with primary infection". Science. 261 (5125): 1179–81. Bibcode:1993Sci...261.1179Z. doi:10.1126/science.8356453. PMID 8356453.
Jump up ^ van't Wout AB, Kootstra NA, Mulder-Kampinga GA, Albrecht-van Lent N, Scherpbier HJ, Veenstra J, Boer K, Coutinho RA, Miedema F, Schuitemaker H (1994). "Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission". Journal of Clinical Investigation. 94 (5): 2060–7. doi:10.1172/JCI117560. PMC 294642  . PMID 7962552.
Jump up ^ Zhu T, Wang N, Carr A, Nam DS, Moor-Jankowski R, Cooper DA, Ho DD (1996). "Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission". Journal of Virology. 70 (5): 3098–107. PMC 190172  . PMID 8627789.
Jump up ^ Clevestig P, Maljkovic I, Casper C, Carlenor E, Lindgren S, Navér L, Bohlin AB, Fenyö EM, Leitner T, Ehrnst A (2005). "The X4 phenotype of HIV type 1 evolves from R5 in two children of mothers, carrying X4, and is not linked to transmission". AIDS Research and Human Retroviruses. 21 (5): 371–8. doi:10.1089/aid.2005.21.371. PMID 15929699.
Jump up ^ Moore JP (1997). "Coreceptors: implications for HIV pathogenesis and therapy". Science. 276 (5309): 51–2. doi:10.1126/science.276.5309.51. PMID 9122710.
Jump up ^ Karlsson A, Parsmyr K, Aperia K, Sandström E, Fenyö EM, Albert J (1994). "MT-2 cell tropism of human immunodeficiency virus type 1 isolates as a marker for response to treatment and development of drug resistance". The Journal of Infectious Diseases. 170 (6): 1367–75. doi:10.1093/infdis/170.6.1367. PMID 7995974.
Jump up ^ Koot M, van 't Wout AB, Kootstra NA, de Goede RE, Tersmette M, Schuitemaker H (1996). "Relation between changes in cellular load, evolution of viral phenotype, and the clonal composition of virus populations in the course of human immunodeficiency virus type 1 infection". The Journal of Infectious Diseases. 173 (2): 349–54. doi:10.1093/infdis/173.2.349. PMID 8568295.
Jump up ^ Cheney K, McKnight A (2010). "HIV-2 Tropism and Disease". Lentiviruses and Macrophages: Molecular and Cellular Interactions. Caister Academic Press. ISBN 978-1-904455-60-8. [page needed]
^ Jump up to: a b c d e f g Chan DC, Kim PS (1998). "HIV entry and its inhibition". Cell. 93 (5): 681–4. doi:10.1016/S0092-8674(00)81430-0. PMID 9630213.
^ Jump up to: a b c d e f Wyatt R, Sodroski J (1998). "The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens". Science. 280 (5371): 1884–8. Bibcode:1998Sci...280.1884W. doi:10.1126/science.280.5371.1884. PMID 9632381.
^ Jump up to: a b Arthos J, Cicala C, Martinelli E, Macleod K, Van Ryk D, Wei D, Xiao Z, Veenstra TD, Conrad TP, Lempicki RA, McLaughlin S, Pascuccio M, Gopaul R, McNally J, Cruz CC, Censoplano N, Chung E, Reitano KN, Kottilil S, Goode DJ, Fauci AS (2008). "HIV-1 envelope protein binds to and signals through integrin alpha(4)beta(7), the gut mucosal homing receptor for peripheral T cells". Nature Immunology. 9 (3): 301–9. doi:10.1038/ni1566. PMID 18264102.
^ Jump up to: a b Pope M, Haase AT (2003). "Transmission, acute HIV-1 infection and the quest for strategies to prevent infection". Nature Medicine. 9 (7): 847–52. doi:10.1038/nm0703-847. PMID 12835704.
Jump up ^ Haedicke J, Brown C, Naghavi MH (Aug 2009). "The brain-specific factor FEZ1 is a determinant of neuronal susceptibility to HIV-1 infection". Proceedings of the National Academy of Sciences. 106 (33): 14040–14045. Bibcode:2009PNAS..10614040H. doi:10.1073/pnas.0900502106. PMC 2729016  . PMID 19667186.
Jump up ^ Daecke J, Fackler OT, Dittmar MT, Kräusslich HG (2005). "Involvement of clathrin-mediated endocytosis in human immunodeficiency virus type 1 entry". Journal of Virology. 79 (3): 1581–1594. doi:10.1128/jvi.79.3.1581-1594.2005. PMC 544101  . PMID 15650184.
Jump up ^ Miyauchi K, Kim Y, Latinovic O, Morozov V, Melikyan GB (2009). "HIV Enters Cells via Endocytosis and Dynamin-Dependent Fusion with Endosomes". Cell. 137 (3): 433–444. doi:10.1016/j.cell.2009.02.046. PMC 2696170  . PMID 19410541.
Jump up ^ Koch P, Lampe M, Godinez WJ, Müller B, Rohr K, Kräusslich HG, Lehmann MJ (2009). "Visualizing fusion of pseudotyped HIV-1 particles in real time by live cell microscopy". Retrovirology. 6: 84. doi:10.1186/1742-4690-6-84. PMC 2762461  . PMID 19765276.
Jump up ^ Thorley JA, McKeating JA, Rappoport JZ (2010). "Mechanis ms of viral entry: sneaking in the front door". Protoplasma. 244 (1–4): 15–24. doi:10.1007/s00709-010-0152-6. PMC 3038234  . PMID 20446005.
Jump up ^ Permanyer M, Ballana E, Esté JA (2010). "Endocytosis of HIV: anything goes". Trends in Microbiology. 18 (12): 543–551. doi:10.1016/j.tim.2010.09.003. PMID 20965729.
^ Jump up to: a b c Zheng YH, Lovsin N, Peterlin BM (2005). "Newly identified host factors modulate HIV replication". Immunology Letters. 97 (2): 225–34. doi:10.1016/j.imlet.2004.11.026. PMID 15752562.
Jump up ^ "IV. Viruses> F. Animal Virus Life Cycles > 3. The Life Cycle of HIV". Doc Kaiser's Microbiology Home Page. Community College of Baltimore County. January 2008. Archived from the original on July 26, 2010.
Jump up ^ Hiscott J, Kwon H, Génin P (2001). "Hostile takeovers: viral appropriation of the NF-kB pathway". Journal of Clinical Investigation. 107 (2): 143–151. doi:10.1172/JCI11918. PMC 199181  . PMID 11160127.
Jump up ^ Pollard VW, Malim MH (1998). "The HIV-1 Rev protein". Annual Review of Microbiology. 52: 491–532. doi:10.1146/annurev.micro.52.1.491. PMID 9891806.
Jump up ^ Butsch, M.; Boris-Lawrie, K. (2002). "Destiny of Unspliced Retroviral RNA: Ribosome and/or Virion?". Journal of Virology. 76 (7): 3089–94. doi:10.1128/JVI.76.7.3089-3094.2002. PMC 136024  . PMID 11884533.
Jump up ^ Hellmund, Chris; Lever, Andrew M. L. (2016-07-14). "Coordination of Genomic RNA Packaging with Viral Assembly in HIV-1". Viruses. 8 (7): 192. doi:10.3390/v8070192. ISSN 1999-4915. PMC 4974527  . PMID 27428992.
Jump up ^ Ricci, E. P.; Herbreteau, C. H.; Decimo, D.; Schaupp, A.; Datta, S. A. K.; Rein, A.; Darlix, J. -L.; Ohlmann, T. (2008). "In vitro expression of the HIV-2 genomic RNA is controlled by three distinct internal ribosome entry segments that are regulated by the HIV protease and the Gag polyprotein". RNA. 14 (7): 1443–55. doi:10.1261/rna.813608. PMC 2441975  . PMID 18495939.
^ Jump up to: a b Hu WS, Temin HM (1990). "Retroviral recombination and reverse transcription". Science. 250 (4985): 1227–33. Bibcode:1990Sci...250.1227H. doi:10.1126/science.1700865. PMID 1700865.
^ Jump up to: a b Charpentier C, Nora T, Tenaillon O, Clavel F, Hance AJ (2006). "Extensive recombination among human immunodeficiency virus type 1 quasispecies makes an important contribution to viral diversity in individual patients". Journal of Virology. 80 (5): 2472–82. doi:10.1128/JVI.80.5.2472-2482.2006. PMC 1395372  . PMID 16474154.
Jump up ^ Nora T, Charpentier C, Tenaillon O, Hoede C, Clavel F, Hance AJ (2007). "Contribution of recombination to the evolution of human immunodeficiency viruses expressing resistance to antiretroviral treatment". Journal of Virology. 81 (14): 7620–8. doi:10.1128/JVI.00083-07. PMC 1933369  . PMID 17494080.
Jump up ^ Chen J, Powell D, Hu WS (2006). "High frequency of genetic recombination is a common feature of primate lentivirus replication". Journal of Virology. 80 (19): 9651–8. doi:10.1128/JVI.00936-06. PMC 1617242  . PMID 16973569.
^ Jump up to: a b Bonhoeffer S, Chappey C, Parkin NT, Whitcomb JM, Petropoulos CJ (2004). "Evidence for positive epistasis in HIV-1". Science. 306 (5701): 1547–50. Bibcode:2004Sci...306.1547B. doi:10.1126/science.1101786. PMID 15567861.
Jump up ^ Israël N, Gougerot-Pocidalo MA (1997). "Oxidative stress in human immunodeficiency virus infection". Cellular and Molecular Life Sciences. 53 (11–12): 864–70. doi:10.1007/s000180050106. PMID 9447238.
Jump up ^ Michod RE, Bernstein H, Nedelcu AM (May 2008). "Adaptive value of sex in microbial pathogens" (PDF). Infection, Genetics and Evolution. 8 (3): 267–85. doi:10.1016/j.meegid.2008.01.002. PMID 18295550.
Jump up ^ Hallenberger S, Bosch V, Angliker H, Shaw E, Klenk HD, Garten W (November 26, 1992). "Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160". Nature. 360 (6402): 358–61. Bibcode:1992Natur.360..358H. doi:10.1038/360358a0. PMID 1360148.
Jump up ^ Gelderblom HR (1997). "Fine structure of HIV and SIV" (PDF). In Los Alamos National Laboratory. HIV sequence compendium. Los Alamos National Laboratory. pp. 31–44.
^ Jump up to: a b c d Zhang C, Zhou S, Groppelli E, Pellegrino P, Williams I, Borrow P, Chain BM, Jolly C (2015). "Hybrid Spreading Mechanisms and T Cell Activation Shape the Dynamics of HIV-1 Infection". PLOS Computational Biology. 11 (4): e1004179. doi:10.1371/journal.pcbi.1004179. PMC 4383537  . PMID 25837979.
^ Jump up to: a b Jolly C, Kashefi K, Hollinshead M, Sattentau QJ (2004). "HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse". Journal of Experimental Medicine. 199 (2): 283–293. doi:10.1084/jem.20030648. PMC 2211771  . PMID 14734528.
Jump up ^ Sattentau Q (2008). "Avoiding the void: cell-to-cell spread of human viruses". Nature Reviews Microbiology. 6 (11): 815–826. doi:10.1038/nrmicro1972. PMID 18923409.
Jump up ^ Duncan CJ, Russell RA, Sattentau QJ (2013). "High multiplicity HIV-1 cell-to-cell transmission from macrophages to CD4+ T cells limits antiretroviral efficacy". AIDS. 27 (14): 2201–2206. doi:10.1097/QAD.0b013e3283632ec4. PMC 4714465  . PMID 24005480.
Jump up ^ Sewald X, Gonzalez DG, Haberman AM, Mothes W (2012). "In vivo imaging of virological synapses". Nature Communications. 3: 1320. doi:10.1038/ncomms2338. PMC 3784984  . PMID 23271654.
Jump up ^ Sigal A, Kim JT, Balazs AB, Dekel E, Mayo A, Milo R, Baltimore D (2011). "Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy". Nature. 477 (7362): 95–98. doi:10.1038/nature10347. PMID 21849975.
^ Jump up to: a b c d Robertson DL, Hahn BH, Sharp PM (1995). "Recombination in AIDS viruses". Journal of Molecular Evolution. 40 (3): 249–59. doi:10.1007/BF00163230. PMID 7723052.
Jump up ^ Rambaut A, Posada D, Crandall KA, Holmes EC (January 2004). "The causes and consequences of HIV evolution". Nature Reviews Genetics. 5 (52–61): 52–61. doi:10.1038/nrg1246. PMID 14708016.
Jump up ^ Perelson AS, Ribeiro RM (October 2008). "Estimating drug efficacy and viral dynamic parameters: HIV and HCV". Statistics in Medicine. 27 (23): 4647–57. doi:10.1002/sim.3116. PMID 17960579.
^ Jump up to: a b Sodora DL, Allan JS, Apetrei C, Brenchley JM, Douek DC, Else JG, Estes JD, Hahn BH, Hirsch VM, Kaur A, Kirchhoff F, Muller-Trutwin M, Pandrea I, Schmitz JE, Silvestri G (2009). "Toward an AIDS vaccine: lessons from natural simian immunodeficiency virus infections of African nonhuman primate hosts". Nature Medicine. 15 (8): 861–865. doi:10.1038/nm.2013. PMC 2782707  . PMID 19661993.
Jump up ^ Holzammer S, Holznagel E, Kaul A, Kurth R, Norley S (2001). "High virus loads in naturally and experimentally SIVagm-infected African green monkeys". Virology. 283 (2): 324–31. doi:10.1006/viro.2001.0870. PMID 11336557.
Jump up ^ Kurth, R.; Norley, S. (1996). "Why don't the natural hosts of SIV develop simian AIDS?". The Journal of NIH Research. 8: 33–37.
Jump up ^ Baier M, Dittmar MT, Cichutek K, Kurth R (1991). "Development of vivo of genetic variability of simian immunodeficiency virus". Proceedings of the National Academy of Sciences of the United States of America. 88 (18): 8126–30. Bibcode:1991PNAS...88.8126B. doi:10.1073/pnas.88.18.8126. PMC 52459  . PMID 1896460.
Jump up ^ Daniel MD, King NW, Letvin NL, Hunt RD, Sehgal PK, Desrosiers RC (1984). "A new type D retrovirus isolated from macaques with an immunodeficiency syndrome". Science. 223 (4636): 602–5. Bibcode:1984Sci...223..602D. doi:10.1126/science.6695172. PMID 6695172.
^ Jump up to: a b Keele BF, Jones JH, Terio KA, Estes JD, Rudicell RS, Wilson ML, Li Y, Learn GH, Beasley TM, Schumacher-Stankey J, Wroblewski E, Mosser A, Raphael J, Kamenya S, Lonsdorf EV, Travis DA, Mlengeya T, Kinsel MJ, Else JG, Silvestri G, Goodall J, Sharp PM, Shaw GM, Pusey AE, Hahn BH (2009). "Increased mortality and AIDS-like immunopathology in wild chimpanzees infected with SIVcpz". Nature. 460 (7254): 515–519. Bibcode:2009Natur.460..515K. doi:10.1038/nature08200. PMC 2872475  . PMID 19626114.
Jump up ^ Schindler M, Münch J, Kutsch O, Li H, Santiago ML, Bibollet-Ruche F, Müller-Trutwin MC, Novembre FJ, Peeters M, Courgnaud V, Bailes E, Roques P, Sodora DL, Silvestri G, Sharp PM, Hahn BH, Kirchhoff F (2006). "Nef-mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1". Cell. 125 (6): 1055–67. doi:10.1016/j.cell.2006.04.033. PMID 16777597.
Jump up ^ Thomson MM, Pérez-Alvarez L, Nájera R (2002). "Molecular epidemiology of HIV-1 genetic forms and its significance for vaccine development and therapy". The Lancet Infectious Diseases. 2 (8): 461–471. doi:10.1016/S1473-3099(02)00343-2. PMID 12150845.
Jump up ^ Carr JK, Foley BT, Leitner T, Salminen M, Korber B, McCutchan F (1998). "Reference sequences representing the principal genetic diversity of HIV-1 in the pandemic" (PDF). In Los Alamos National Laboratory. HIV sequence compendium. Los Alamos, New Mexico: Los Alamos National Laboratory. pp. 10–19. CS1 maint: Uses authors parameter (link)
Jump up ^ Osmanov S, Pattou C, Walker N, Schwardländer B, Esparza J (2002). "Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000". Acquired Immune Deficiency Syndrome. 29 (2): 184–190. doi:10.1097/00042560-200202010-00013. PMID 11832690.
Jump up ^ Perrin L, Kaiser L, Yerly S (2003). "Travel and the spread of HIV-1 genetic variants". The Lancet Infectious Diseases. 3 (1): 22–27. doi:10.1016/S1473-3099(03)00484-5. PMID 12505029.
^ Jump up to: a b Plantier JC, Leoz M, Dickerson JE, De Oliveira F, Cordonnier F, Lemée V, Damond F, Robertson DL, Simon F (August 2009). "A new human immunodeficiency virus derived from gorillas". Nature Medicine. 15 (8): 871–2. doi:10.1038/nm.2016. PMID 19648927. Lay summary.
Jump up ^ Keele BF, Van Heuverswyn F, Li Y, Bailes E, Takehisa J, Santiago ML, Bibollet-Ruche F, Chen Y, Wain LV, Liegeois F, Loul S, Ngole EM, Bienvenue Y, Delaporte E, Brookfield JF, Sharp PM, Shaw GM, Peeters M, Hahn BH (Jul 28, 2006). "Chimpanzee reservoirs of pandemic and nonpandemic HIV-1". Science. 313 (5786): 523–6. Bibcode:2006Sci...313..523K. doi:10.1126/science.1126531. PMC 2442710  . PMID 16728595.
^ Jump up to: a b c d Kumaranayake, L.; Watts, C. (2001). "Resource allocation and priority setting of HIV/AIDS interventions: addressing the generalized epidemic in sub-Saharan Africa". Journal of International Development. 13 (4): 451–466. doi:10.1002/jid.797.
Jump up ^ Kleinman S (September 2004). "Patient information: Blood donation and transfusion". Uptodate. Archived from the original on April 12, 2008.
^ Jump up to: a b Centers for Disease Control and Prevention (2001). "Revised guidelines for HIV counseling, testing, and referral". MMWR Recommendations and Reports. 50 (RR–19): 1–57. PMID 11718472.
Jump up ^ Celum CL, Coombs RW, Lafferty W, Inui TS, Louie PH, Gates CA, McCreedy BJ, Egan R, Grove T, Alexander S (1991). "Indeterminate human immunodeficiency virus type 1 western blots: seroconversion risk, specificity of supplemental tests, and an algorithm for evaluation". The Journal of Infectious Diseases. 164 (4): 656–664. doi:10.1093/infdis/164.4.656. PMID 1894929.
Jump up ^ "Country Comparison :: HIV/AIDS - Deaths". The World Factbook, Central Intelligence Agency.
^ Jump up to: a b Chou R, Huffman LH, Fu R, Smits AK, Korthuis PT (July 2005). "Screening for HIV: a review of the evidence for the U.S. Preventive Services Task Force". Annals of Internal Medicine. 143 (1): 55–73. doi:10.7326/0003-4819-143-1-200507050-00010. PMID 15998755.
Jump up ^ Tolle MA, Schwarzwald HL (July 15, 2010). "Postexposure prophylaxis against human immunodeficiency virus". American Family Physician. 82 (2): 161–6. PMID 20642270.
Jump up ^ "Quick Reference Guide—Laboratory Testing for the Diagnosis of HIV Infection: Updated Recommendations" (PDF). cdc.gov. New York State Department of Health. June 27, 2014. pp. 1–2. Retrieved April 13, 2017.
Jump up ^ "New CDC Recommendations for HIV Testing in Laboratories" (PDF). cdc.gov. Centers for Disease Control and Prevention. Retrieved April 13, 2017.
Jump up ^ "HIV Treatment: FDA-Approved HIV Medicines". AIDSinfo.
Jump up ^ Bernstein, Ryan Lenora Brown, Lenny. "New HIV vaccine trial, the first in years, to begin". chicagotribune.com. Retrieved 2016-11-28.
Jump up ^ Huang Y, Yu J, Lanzi A, Yao X, Andrews C, Tsai L, Gajjar M, Sun M, Seaman M, Padte N, Ho D (2016). "Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity". Cell. 165 (7): 1621–1631. doi:10.1016/j.cell.2016.05.024. PMC 4972332  . PMID 27315479.
Jump up ^ Bournazos, S., Gazumyan, A., Seaman, M., Nussenzweig, M. and Ravetch, J. (2016). Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency.
Jump up ^ Attia, Suzanna; Egger, Matthias; Müller, Monika; Zwahlen, Marcel; Low, Nicola (2009). "Sexual transmission of HIV according to viral load and antiretroviral therapy: Systematic review and meta-analysis". AIDS. 23 (11): 1397–404. doi:10.1097/QAD.0b013e32832b7dca. PMID 19381076.
Jump up ^ Wilson, David P; Law, Matthew G; Grulich, Andrew E; Cooper, David A; Kaldor, John M (2008). "Relation between HIV viral load and infectiousness: A model-based analysis". The Lancet. 372 (9635): 314–20. doi:10.1016/S0140-6736(08)61115-0. PMID 18657710.
Jump up ^ Cohen, Myron S; Chen, Ying Q; McCauley, Marybeth; Gamble, Theresa; Hosseinipour, Mina C; Kumarasamy, Nagalingeswaran; Hakim, James G; Kumwenda, Johnstone; Grinsztejn, Beatriz; Pilotto, Jose H.S; Godbole, Sheela V; Mehendale, Sanjay; Chariyalertsak, Suwat; Santos, Breno R; Mayer, Kenneth H; Hoffman, Irving F; Eshleman, Susan H; Piwowar-Manning, Estelle; Wang, Lei; Makhema, Joseph; Mills, Lisa A; De Bruyn, Guy; Sanne, Ian; Eron, Joseph; Gallant, Joel; Havlir, Diane; Swindells, Susan; Ribaudo, Heather; Elharrar, Vanessa; et al. (2011). "Prevention of HIV-1 Infection with Early Antiretroviral Therapy". New England Journal of Medicine. 365 (6): 493–505. doi:10.1056/NEJMoa1105243. PMC 3200068  . PMID 21767103.
Jump up ^ "HIV Consensus Statement". Prevention Access Campaign. November 19, 2017.
Jump up ^ Mandell, Gerald L.; Bennett, John E.; Dolin, Raphael, eds. (2010). "Chapter 169". Mandell, Douglas, and Bennett's principles and practice of infectious diseases (7th ed.). Philadelphia: Churchill Livingstone/Elsevier. ISBN 978-0-443-06839-3. [page needed]
Jump up ^ Gottlieb MS (2006). "Pneumocystis pneumonia—Los Angeles. 1981". American Journal of Public Health. 96 (6): 980–1; discussion 982–3. doi:10.2105/AJPH.96.6.980. PMC 1470612  . PMID 16714472. Archived from the original on April 22, 2009.
Jump up ^ Friedman-Kien AE (October 1981). "Disseminated Kaposi's sarcoma syndrome in young homosexual men". Journal of the American Academy of Dermatology. 5 (4): 468–71. doi:10.1016/S0190-9622(81)80010-2. PMID 7287964.
Jump up ^ Hymes KB, Cheung T, Greene JB, Prose NS, Marcus A, Ballard H, William DC, Laubenstein LJ (September 1981). "Kaposi's sarcoma in homosexual men-a report of eight cases". The Lancet. 2 (8247): 598–600. doi:10.1016/S0140-6736(81)92740-9. PMID 6116083.
^ Jump up to: a b Basavapathruni A, Anderson KS (December 2007). "Reverse transcription of the HIV-1 pandemic". The FASEB Journal. 21 (14): 3795–3808. doi:10.1096/fj.07-8697rev. PMID 17639073.
Jump up ^ Lederberg, Joshua, ed. (2000). Encyclopedia of Microbiology (2nd ed.). Burlington: Elsevier. p. 106. ISBN 978-0-08-054848-7. Retrieved 9 June 2016.
Jump up ^ Centers for Disease Control (1982). "Persistent, generalized lymphadenopathy among homosexual males". Morbidity and Mortality Weekly Report. 31 (19): 249–251. PMID 6808340.
Jump up ^ Barré-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, Dauguet C, Axler-Blin C, Vézinet-Brun F, Rouzioux C, Rozenbaum W, Montagnier L (1983). "Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)". Science. 220 (4599): 868–871. Bibcode:1983Sci...220..868B. doi:10.1126/science.6189183. PMID 6189183.
^ Jump up to: a b Centers for Disease Control (1982). "Opportunistic infections and Kaposi's sarcoma among Haitians in the United States". Morbidity and Mortality Weekly Report. 31 (26): 353–354; 360–361. PMID 6811853.
Jump up ^ Altman LK (May 11, 1982). "New homosexual disorder worries health officials". The New York Times. Retrieved August 31, 2011.
Jump up ^ Gilman, Sander L., ed. (1987). "AIDS and Syphilis: The Iconography of Disease". Retrieved 25 April 2015.
Jump up ^ "Making Headway Under Hellacious Circumstances" (PDF). American Association for the Advancement of Science. July 28, 2006. Retrieved June 23, 2008.
Jump up ^ Kher U (July 27, 1982). "A Name for the Plague". Time. Archived from the original on March 7, 2008. Retrieved March 10, 2008.
Jump up ^ Centers for Disease Control (1982). "Update on acquired immune deficiency syndrome (AIDS)—United States". Morbidity and Mortality Weekly Report. 31 (37): 507–508; 513–514. PMID 6815471.
Jump up ^ Gallo RC, Sarin PS, Gelmann EP, Robert-Guroff M, Richardson E, Kalyanaraman VS, Mann D, Sidhu GD, Stahl RE, Zolla-Pazner S, Leibowitch J, Popovic M (1983). "Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS)". Science. 220 (4599): 865–867. Bibcode:1983Sci...220..865G. doi:10.1126/science.6601823. PMID 6601823.
Jump up ^ Barré-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, Dauguet C, Axler-Blin C, Vézinet-Brun F, Rouzioux C, Rozenbaum W, Montagnier L (1983). "Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)". Science. 220 (4599): 868–871. Bibcode:1983Sci...220..868B. doi:10.1126/science.6189183. PMID 6189183.
Jump up ^ "The 2008 Nobel Prize in Physiology or Medicine - Press Release". www.nobelprize.org. Retrieved 2018-01-28.
Jump up ^ Aldrich, Robert; Wotherspoon, Garry, eds. (2001). Who's who in gay and lesbian history. London: Routledge. p. 154. ISBN 978-0-415-22974-6.
Jump up ^ Levy JA; et al. (1984). "Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS". Science. 225: 840–842. doi:10.1126/science.6206563. CS1 maint: Explicit use of et al. (link)
Jump up ^ Levy JA, Kaminsky LS, Morrow WJW, Steimer K, Luciw P, Dina D, Hoxie J, Oshiro L (1985). "Infection by the retrovirus associated with the acquired immunodeficiency syndrome". Annals of Internal Medicine. 103: 694–699. doi:10.7326/0003-4819-103-5-694. CS1 maint: Multiple names: authors list (link)
Jump up ^ Sharp PM, Hahn BH (2011). "Origins of HIV and the AIDS Pandemic". Cold Spring Harbor perspectives in medicine. 1 (1): a006841. doi:10.1101/cshperspect.a006841. PMC 3234451  . PMID 22229120.
Jump up ^ Faria NR, Rambaut A, Suchard MA, Baele G, Bedford T, Ward MJ, Tatem AJ, Sousa JD, Arinaminpathy N, Pépin J, Posada D, Peeters M, Pybus OG, Lemey P (2014). "The early spread and epidemic ignition of HIV-1 in human populations". Science. 346 (6205): 56–61. doi:10.1126/science.1256739. PMC 4254776  . PMID 25278604.
Jump up ^ Gao F, Bailes E, Robertson DL, Chen Y, Rodenburg CM, Michael SF, Cummins LB, Arthur LO, Peeters M, Shaw GM, Sharp PM, Hahn BH (1999). "Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes". Nature. 397 (6718): 436–41. Bibcode:1999Natur.397..436G. doi:10.1038/17130. PMID 9989410.
Jump up ^ Keele BF, Van Heuverswyn F, Li Y, Bailes E, Takehisa J, Santiago ML, Bibollet-Ruche F, Chen Y, Wain LV, Liegeois F, Loul S, Ngole EM, Bienvenue Y, Delaporte E, Brookfield JF, Sharp PM, Shaw GM, Peeters M, Hahn BH (2006). "Chimpanzee reservoirs of pandemic and nonpandemic HIV-1". Science. 313 (5786): 523–6. Bibcode:2006Sci...313..523K. doi:10.1126/science.1126531. PMC 2442710  . PMID 16728595.
Jump up ^ Goodier JL, Kazazian HH (2008). "Retrotransposons revisited: the restraint and rehabilitation of parasites". Cell. 135 (1): 23–35. doi:10.1016/j.cell.2008.09.022. PMID 18854152.
Jump up ^ Sharp PM, Bailes E, Chaudhuri RR, Rodenburg CM, Santiago MO, Hahn BH (2001). "The origins of acquired immune deficiency syndrome viruses: where and when?" (PDF). Philosophical Transactions of the Royal Society B. 356 (1410): 867–76. doi:10.1098/rstb.2001.0863. PMC 1088480  . PMID 11405934.
Jump up ^ Kalish ML, Wolfe ND, Ndongmo CB, McNicholl J, Robbins KE, Aidoo M, Fonjungo PN, Alemnji G, Zeh C, Djoko CF, Mpoudi-Ngole E, Burke DS, Folks TM (2005). "Central African hunters exposed to simian immunodeficiency virus". Emerging Infectious Diseases. 11 (12): 1928–30. doi:10.3201/eid1112.050394. PMC 3367631  . PMID 16485481.
^ Jump up to: a b Marx PA, Alcabes PG, Drucker E (2001). "Serial human passage of simian immunodeficiency virus by unsterile injections and the emergence of epidemic human immunodeficiency virus in Africa" (PDF). Philosophical Transactions of the Royal Society B. 356 (1410): 911–20. doi:10.1098/rstb.2001.0867. PMC 1088484  . PMID 11405938.
Jump up ^ Worobey M, Gemmel M, Teuwen DE, Haselkorn T, Kunstman K, Bunce M, Muyembe JJ, Kabongo JM, Kalengayi RM, Van Marck E, Gilbert MT, Wolinsky SM (2008). "Direct evidence of extensive diversity of HIV-1 in Kinshasa by 1960". Nature. 455 (7213): 661–4. Bibcode:2008Natur.455..661W. doi:10.1038/nature07390. PMC 3682493  . PMID 18833279.
^ Jump up to: a b de Sousa JD, Müller V, Lemey P, Vandamme AM (2010). Martin DP, ed. "High GUD incidence in the early 20th century created a particularly permissive time window for the origin and initial spread of epidemic HIV strains". PLOS One. 5 (4): e9936. doi:10.1371/journal.pone.0009936. PMC 2848574  . PMID 20376191.
Jump up ^ Chitnis A, Rawls D, Moore J (2000). "Origin of HIV type 1 in colonial French equatorial Africa?". AIDS Research and Human Retroviruses. 16 (1): 5–8. doi:10.1089/088922200309548. PMID 10628811.
Jump up ^ Donald McNeil, Jr. (September 16, 2010). "Precursor to H.I.V. was in monkeys for millennia". The New York Times. Retrieved September 17, 2010. Dr. Marx believes that the crucial event was the introduction into Africa of millions of inexpensive, mass-produced syringes in the 1950s. ... suspect that the growth of colonial cities is to blame. Before 1910, no Central African town had more than 10,000 people. But urban migration rose, increasing sexual contacts and leading to red-light districts.
Jump up ^ Zhu T, Korber BT, Nahmias AJ, Hooper E, Sharp PM, Ho DD (1998). "An African HIV-1 Sequence from 1959 and Implications for the Origin of the epidemic". Nature. 391 (6667): 594–7. Bibcode:1998Natur.391..594Z. doi:10.1038/35400. PMID 9468138.
Jump up ^ Kolata, Gina (October 28, 1987). "Boy's 1969 death suggests AIDS invaded U.S. several times". The New York Times. Retrieved February 11, 2009.
Further reading
Berlier W, Bourlet T, Lawrence P, Hamzeh H, Lambert C, Genin C, Verrier B, Dieu-Nosjean MC, Pozzetto B, Delézay O (2005). "Selective sequestration of X4 isolates by human genital epithelial cells: Implication for virus tropism selection process during sexual transmission of HIV". Journal of Medical Virology. 77 (4): 465–74. doi:10.1002/jmv.20478. PMID 16254974.
Joint United Nations Programme on HIV/AIDS (UNAIDS) (2011). Global HIV/AIDS Response, Epidemic update and health sector progress towards universal access (PDF). Joint United Nations Programme on HIV/AIDS.
Muciaccia B, Padula F, Vicini E, Gandini L, Lenzi A, Stefanini M (2005). "Beta-chemokine receptors 5 and 3 are expressed on the head region of human spermatozoon". The FASEB Journal. 19 (14): 2048–50. doi:10.1096/fj.05-3962fje. PMID 16174786.
External links
Find more aboutHIVat Wikipedia's sister projects
Definitions from Wiktionary
Media from Wikimedia Commons
News from Wikinews
Textbooks from Wikibooks
HIV/AIDS at Curlie (based on DMOZ)
[show]
v
t
e
HIV/AIDS topics
[show]
HIV/AIDS
HIV
HIV
structure and genome
subtypes
CDC classification
disease progression rates
HIV/AIDS
diagnosis
management
pathophysiology
prevention
research
vaccination
PrEP
WHO disease staging system for HIV infection and disease
Children
Teens / Adults
Countries by AIDS prevalence rate
Conditions
Signs and symptoms
AIDS-defining clinical condition
Diffuse infiltrative lymphocytosis syndrome
Lipodystrophy
Nephropathy
Neurocognitive disorders
Pruritus
Superinfection
Tuberculosis co-infection
HIV Drug Resistance Database
Innate resistance to HIV
History
History
Epidemiology
Multiple sex partners
Timeline
AIDS Museum
Timothy Ray Brown
Social
AIDS orphan
Catholic Church and HIV/AIDS
Circumcision and HIV
Criminal transmission
Discrimination against people
Economic impact
HIV-affected community
HIV/AIDS denialism
Safe sex
Sex education
List of HIV-positive people
People With AIDS Self-Empowerment Movement
Culture
International AIDS Conference
International AIDS Society
Joint United Nations Programme on HIV/AIDS (UNAIDS)
President's Emergency Plan for AIDS Relief (PEPFAR)
Treatment Action Campaign
World AIDS Day
Media portrayal of HIV/AIDS
Misconceptions about HIV/AIDS
Discredited HIV/AIDS origins theories
[show]
AIDS pandemic by region / country
Africa
Angola
Benin
Botswana
Democratic Republic of the Congo
Egypt
Ethiopia
Ghana
Guinea
Côte d'Ivoire (Ivory Coast)
Kenya
Lesotho
Madagascar
Malawi
Mali
Mozambique
Namibia
Niger
Nigeria
Rwanda
Senegal
Swaziland
Tanzania
South Africa
Uganda
Zambia
Zimbabwe
North America
Canada
Mexico
El Salvador
Guatemala
Honduras
Nicaragua
United States
New York City
Caribbean
Haiti
Jamaica
Dominican Republic
South America
Bolivia
Brazil
Colombia
Guyana
Peru
Asia
Bangladesh
Bhutan
Myanmar (Burma)
Cambodia
China (PRC) (Yunnan)
East Timor
India
Indonesia
Iraq
Japan
Jordan
Laos
Nepal
North Korea
Pakistan
Philippines
Thailand
Taiwan (ROC)
United Arab Emirates
Vietnam
Europe
United Kingdom
Russia
Ukraine
Oceania
Australia
New Zealand
Papua New Guinea
List of countries by HIV/AIDS adult prevalence rate
List of HIV/AIDS cases and deaths registered by region
[show]
v
t
e
Sexually transmitted infection (STI) (primarily A50–A64, 090–099)
Bacterial
Chancroid (Haemophilus ducreyi)
Chlamydia/Lymphogranuloma venereum (Chlamydia trachomatis)
Donovanosis or Granuloma Inguinale (Klebsiella granulomatis)
Gonorrhea (Neisseria gonorrhoeae)
Mycoplasma hominis infection (Mycoplasma hominis)
Syphilis (Treponema pallidum)
Ureaplasma infection (Ureaplasma urealyticum)
Protozoal
Trichomoniasis (Trichomonas vaginalis)
Parasitic
Crab louse/crabs
Scabies
Viral
AIDS (HIV-1/HIV-2)
Cervical cancer, vulvar cancer & Genital warts (condyloma), Penile cancer, Anal cancer (Human papillomavirus (HPV))
Hepatitis B (Hepatitis B virus)
Herpes simplex (HSV1/HSV2)
Molluscum contagiosum (MCV)
General
inflammation
female
Cervicitis
Pelvic inflammatory disease (PID)
male
Epididymitis
Prostatitis
either
Proctitis
Urethritis/Non-gonococcal urethritis (NGU)
[show]
v
t
e
Virus: Retroviruses
ssRNA-RT virus
Retroviridae
Alpharetrovirus
Avian sarcoma leukosis virus
Rous sarcoma virus
Betaretrovirus
Mouse mammary tumor virus
Jaagsiekte sheep retrovirus
Deltaretrovirus
Human T-lymphotropic virus (HTLV-1
HTLV-2, 3, 4)
Simian-T-lymphotropic virus (types 1-4)
Bovine leukemia virus
Epsilonretrovirus
Walleye epidermal hyperplasia virus
Gammaretrovirus
Murine leukemia virus
Abelson murine leukemia virus
Friend virus
Feline leukemia virus
Koala retrovirus (KIDS)
Xenotropic murine leukemia virus-related virus
Lentivirus
HIV
Simian immunodeficiency virus (SIV)
Feline immunodeficiency virus (FIV)
Puma lentivirus
Equine infectious anemia
Bovine immunodeficiency virus (BIV)
Caprine arthritis encephalitis virus
Visna virus
Spumavirus
Simian foamy virus
Human foamy virus
Other
Metaviridae
Pseudoviridae
dsDNA-RT virus
Hepadnaviridae (Hepatitis B virus)
Caulimoviridae
Endogenous
ERVWE1
HCP5
Human teratocarcinoma-derived virus
[show]
v
t
e
Breakthrough of the Year
Science
journal
1996: HIV understanding
1997: Dolly the sheep
1998: Accelerating universe
1999: Stem cell
2000: Whole genome sequencing
2001: Nanocircuits or Molecular circuit
2002: RNA interference
2003: Dark energy
2004: Spirit rover
2005: Evolution in action
2006: Poincaré conjecture proof
2007: Human genetic variation
2008: Cellular reprogramming
2009: Ardipithecus ramidus
2010: First quantum machine
2011: HPTN 052 clinical trial
2012: Higgs boson discovery
2013: Cancer immunotherapy
2014: Rosetta comet mission
2015: CRISPR genome-editing method
2016: First observation of gravitational waves
2017: GW170817 (neutron star merger)
Authority control
LCCN: sh86004391
GND: 4200792-6
SUDOC: 028936868
BNF: cb12066922x (data)
BNE: XX534964
Retrieved from "https://en.wikipedia.org/w/index.php?title=HIV&oldid=824620534"
Categories:
HIV/AIDS
Causes of death
Discovery and invention controversies
IARC Group 2B carcinogens
Lentiviruses
Sexually transmitted diseases and infections
Hidden categories:
Wikipedia articles needing page number citations from December 2017
CS1 maint: Uses authors parameter
CS1 maint: Explicit use of et al.
CS1 maint: Multiple names: authors list
Wikipedia indefinitely semi-protected pages
Good articles
Use mdy dates from June 2013
Articles with 'species' microformats
All articles with failed verification
Articles with failed verification from April 2014
All articles with unsourced statements
Articles with unsourced statements from February 2015
Articles with unsourced statements from November 2014
Wikipedia articles in need of updating from January 2013
All Wikipedia articles in need of updating
Articles with Curlie links
Wikipedia articles with LCCN identifiers
Wikipedia articles with GND identifiers
Wikipedia articles with BNF identifiers
Navigation menu
Personal tools
Not logged in
Talk
Contributions
Create account
Log in
Namespaces
Article
Talk
Variants
Views
Read
View source
View history
More
Search
Navigation
Main page
Contents
Featured content
Current events
Random article
Donate to Wikipedia
Wikipedia store
Interaction
Help
About Wikipedia
Community portal
Recent changes
Contact page
Tools
What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Wikidata item
Cite this page
Print/export
Create a book
Download as PDF
Printable version
In other projects
Wikimedia Commons
Wikispecies
Languages
Afrikaans
Alemannisch
አማርኛ
العربية
Asturianu
Azərbaycanca
বাংলা
Bân-lâm-gú
Беларуская
Беларуская (тарашкевіца)
Български
Bosanski
Буряад
Català
Čeština
Cymraeg
Dansk
Deutsch
Eesti
Ελληνικά
Español
Esperanto
Euskara
فارسی
Français
Frysk
Gaeilge
Galego
한국어
Հայերեն
हिन्दी
Hrvatski
Ilokano
Bahasa Indonesia
ᐃᓄᒃᑎᑐᑦ/inuktitut
Íslenska
Italiano
עברית
ಕನ್ನಡ
Kurdî
Кыргызча
Latina
Latviešu
Lietuvių
Lingála
Magyar
Македонски
മലയാളം
मराठी
Bahasa Melayu
Nederlands
नेपाली
日本語
Norsk
Occitan
Олык марий
ଓଡ଼ିଆ
پښتو
Polski
Português
Română
Русский
Scots
Shqip
සිංහල
Simple English
Slovenčina
Slovenščina
کوردی
Српски / srpski
Srpskohrvatski / српскохрватски
Basa Sunda
Suomi
Svenska
Tagalog
தமிழ்
ไทย
Türkçe
Türkmençe
Українська
Tiếng Việt
Võro
Winaray
Yorùbá
粵語
Zazaki
中文
Edit links
This page was last edited on 8 February 2018, at 13:46.
Text is available under the Creative Commons Attribution-ShareAlike License; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.
Privacy policy
About Wikipedia
Disclaimers
Contact Wikipedia
Developers
Cookie statement
Mobile view
Enable previews

key: html

type: local

value: div

attrs: id class

values: mw-page-base noprint

values: mw-head-base noprint

value: a

value: img

attrs: alt src width height srcset data-file-width data-file-height

values: This is a good article. Follow the link for more information.

values: mw-indicator-good-star mw-indicator

values: mw-indicator-pp-default mw-indicator

attrs: id class lang

values: firstHeading firstHeading en

values: siteSub noprint

values: jump-to-nav mw-jump

attrs: href class title

values:
/wiki/HIV_(disambiguation)
mw-disambig
HIV (disambiguation)

attrs: role class

values:
note
hatnote navigation-not-searchable

value: i

values: text-align: center; background-color: rgb(250,250,190)

value: tr

values: min-width:15em; text-align: center; background-color: rgb(250,250,190)

values:
/wiki/SsRNA-RT_virus
mw-redirect
SsRNA-RT virus

values: text-align: left; width: 200px; font-size: 100%

values:
/wiki/CD8_cytotoxic_lymphocyte
mw-redirect
CD8 cytotoxic lymphocyte

values:
/wiki/Transcription_(genetics)
mw-redirect
Transcription (genetics)

attrs: alt src width height class srcset data-file-width data-file-height

values:
/wiki/Aspartyl_protease
mw-redirect
Aspartyl protease

values:
/wiki/Viral_tropism
mw-redirect
Viral tropism

values:
/wiki/Helper_T_cell
mw-redirect
Helper T cell

values:
/wiki/Microglial_cell
mw-redirect
Microglial cell

values:
/wiki/SDF-1_(biology)
mw-redirect
SDF-1 (biology)

values:
/wiki/Myeloid_dendritic_cells
mw-redirect
Myeloid dendritic cells

values:
/wiki/Seminal_fluid
mw-redirect
Seminal fluid

values:
/wiki/Virological_synapse
mw-redirect
Virological synapse

values: The material near this tag failed verification of its source citation(s). (April 2014)

values:
/wiki/Resistance_to_antiviral_drugs
mw-redirect
Resistance to antiviral drugs

values:
/wiki/Translation_(genetics)
mw-redirect
Translation (genetics)

values: This claim needs references to reliable sources. (February 2015)

values:
noprint Inline-Template Template-Fact
white-space:nowrap;

values:
/wiki/Plasma_membrane
mw-redirect
Plasma membrane

values:
/wiki/Antiretroviral_drug
mw-redirect
Antiretroviral drug

values:
/wiki/DNA_sequence
mw-redirect
DNA sequence

values:
/wiki/Gorilla_gorilla
mw-redirect
Gorilla gorilla

values: This claim needs references to reliable sources. (November 2014)

values: display: inline-block; vertical-align: middle; width: 2em; height: 0px; border-style: none; border-top: 2px dotted #000; border-top: blue solid 2px;

values: display: inline-block; vertical-align: middle; width: 2em; height: 0px; border-style: none; border-top: 2px dotted #000; border-top: red solid 2px;

values:
/wiki/Enzyme-linked_immunosorbent_assay
mw-redirect
Enzyme-linked immunosorbent assay

values:
/wiki/Immunofluorescence_assay
mw-redirect
Immunofluorescence assay

values: position:absolute;width:100px;line-height:0;right:100px; top:100px; border-width:96.521755673338px 26.144802193483px 0 0; border-top-color:#033e88

values: position:absolute;line-height:0;border-style:solid;left:0;top:0;border-width:0 200px 100px 0;border-color:#033e88

values: position:absolute;width:100px;line-height:0;right:100px; top:100px; border-width:92.218747234955px 38.674315228786px 0 0; border-top-color:#add2d5

values: position:absolute;line-height:0;border-style:solid;left:0;top:0;border-width:0 200px 100px 0;border-color:#add2d5

values: position:absolute;width:100px;line-height:0;right:100px; top:100px; border-width:86.106169723366px 50.850049513947px 0 0; border-top-color:#5d2e68

values: position:absolute;line-height:0;border-style:solid;left:0;top:0;border-width:0 200px 100px 0;border-color:#5d2e68

values: position:absolute;width:100px;line-height:0;right:100px; top:100px; border-width:75.301240652807px 65.800631882589px 0 0; border-top-color:#536cb6

values: position:absolute;line-height:0;border-style:solid;left:0;top:0;border-width:0 200px 100px 0;border-color:#536cb6

values: position:absolute;width:100px;line-height:0;right:100px; top:100px; border-width:61.785961309034px 78.628843213662px 0 0; border-top-color:#704045

values: position:absolute;line-height:0;border-style:solid;left:0;top:0;border-width:0 200px 100px 0;border-color:#704045

values: position:absolute;width:100px;line-height:0;right:100px; top:100px; border-width:46.069556263528px 88.755822263566px 0 0; border-top-color:#FFA500

values: position:absolute;line-height:0;border-style:solid;left:0;top:0;border-width:0 200px 100px 0;border-color:#FFA500

values: position:absolute;width:100px;line-height:0;right:100px; top:100px; border-width:28.381452374056px 95.887919787318px 0 0; border-top-color:#7953c1

values: position:absolute;line-height:0;border-style:solid;left:0;top:0;border-width:0 200px 100px 0;border-color:#7953c1

values: position:absolute;width:100px;line-height:0;right:100px; top:100px; border-width:9.3482764752599px 99.562089808029px 0 0; border-top-color:#808000

values: position:absolute;line-height:0;border-style:solid;left:0;top:0;border-width:0 200px 100px 0;border-color:#808000

values: position:absolute;width:100px;line-height:0;right:100px; top:0; border-width:0 791.5815088306px 100px 0; border-right-color:#00058f

values: position:absolute;line-height:0;border-style:solid;right:0;top:0;border-width:0 100px 100px 0;border-color:#00058f

values: position:absolute;width:100px;line-height:0;right:100px; top:0; border-width:0 249.77000638277px 100px 0; border-right-color:#008000

values: position:absolute;line-height:0;border-style:solid;right:0;top:0;border-width:0 100px 100px 0;border-color:#008000

values: position:absolute;width:100px;line-height:0;right:100px; top:0; border-width:0 133.5366571299px 100px 0; border-right-color:#800080

values: position:absolute;line-height:0;border-style:solid;right:0;top:0;border-width:0 100px 100px 0;border-color:#800080

values: position:absolute;width:100px;line-height:0;right:100px; top:0; border-width:0 20.84009158137px 100px 0; border-right-color:#FF0000

values: position:absolute;line-height:0;border-style:solid;right:0;top:0;border-width:0 100px 100px 0;border-color:#FF0000

values: position:absolute;width:100px;line-height:0;left:100px; top:16.384784242585px; border-width:0 0 83.615215757415px 54.849755640667px; border-bottom-color:silver

values: display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color:silver; color:black; font-size:100%; text-align:center;

values: -webkit-column-break-inside: avoid;page-break-inside: avoid;break-inside: avoid-column

values: display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #FF0000; color:black; font-size:100%; text-align:center;

values: display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #800080; color:black; font-size:100%; text-align:center;

values: display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #008000; color:black; font-size:100%; text-align:center;

values: display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #00058f; color:black; font-size:100%; text-align:center;

values: display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #808000; color:black; font-size:100%; text-align:center;

values: display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #7953c1; color:black; font-size:100%; text-align:center;

values: display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #FFA500; color:black; font-size:100%; text-align:center;

values: display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #704045; color:black; font-size:100%; text-align:center;

values: display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #536cb6; color:black; font-size:100%; text-align:center;

values: display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #5d2e68; color:black; font-size:100%; text-align:center;

values: display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #add2d5; color:black; font-size:100%; text-align:center;

values: display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color: #033e88; color:black; font-size:100%; text-align:center;

values: display:inline-block; width:1.5em; height:1.5em; margin:1px 0; border:1px solid black; background-color:white; color:black; font-size:100%; text-align:center;

values: The date of the event predicted near this tag has passed. (January 2013)

values: Wikipedia:Manual of Style/Dates and numbers

values: Centers for Disease Control and Prevention (CDC)

values:
/wiki/Health_interventions
mw-redirect
Health interventions

values: Microbicides for sexually transmitted diseases

values:
/wiki/Biological_clock_(aging)
mw-redirect
Biological clock (aging)

values:
/wiki/Pneumocystis_carinii
mw-redirect
Pneumocystis carinii

values: Centers for Disease Control and Prevention

values:
/wiki/Gay_community
mw-redirect
Gay community

values:
/wiki/Virus_structure
mw-redirect
Virus structure

values:
/wiki/African_green_monkey
mw-redirect
African green monkey

values:
/wiki/Sexually_transmitted_disease
mw-redirect
Sexually transmitted disease

values: display:table-cell;padding:0.2em 0.2em 0.2em 0.3em;vertical-align:middle

values: margin:0.5em 0 0.5em 1em;border:solid #aaa 1px

values: Discovery and development of HIV-protease inhibitors

values:
nofollow
external text
//doi.org/10.1126%2Fscience.8493571

values:
/wiki/PubMed_Identifier
mw-redirect
PubMed Identifier

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/8493571

attrs: alt src title width height srcset data-file-width data-file-height

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/18947296

values: Joint United Nations Programme on HIV/AIDS

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/22719248

values:
nofollow
external text
//www.worldcat.org/oclc/192042314

values:
nofollow
external text
//doi.org/10.1289%2Fehp.116-a426

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/18941560

values:
nofollow
external text
//doi.org/10.1016%2Fj.mib.2010.06.002

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/20598938

values:
nofollow
external text
//doi.org/10.1038%2Fnature12940

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/24356306

values:
nofollow
external text
//doi.org/10.3390%2Fv4113020

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/23202514

values: International Committee on Taxonomy of Viruses

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/8280406

values:
nofollow
external text
//doi.org/10.1021%2Fcb600131q

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/17163676

values:
nofollow
external text
//doi.org/10.1002%2Fsim.1342

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/12590415

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/12029140

values:
nofollow
external text
//doi.org/10.1021%2Fjm010533y

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/11931626

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/9108481

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/20523901

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/26972002

values:
nofollow
external text
//doi.org/10.1038%2Fncomms8479

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/26105115

values:
nofollow
external text
//doi.org/10.1128%2FJVI.01190-15

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/26085151

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/25747313

values:
nofollow
external text
//doi.org/10.1126%2Fscience.1245625

values:
nofollow
external text
//www.worldcat.org/issn/1095-9203

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/24179159

values:
nofollow
external text
//doi.org/10.1126%2Fscience.1245627

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/24179160

values:
nofollow
external text
//www.worldcat.org/issn/1553-7374

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/24068931

values:
nofollow
external text
//www.worldcat.org/issn/2211-1247

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/26051934

values:
nofollow
external text
//doi.org/10.1016%2Fj.cell.2015.11.056

values:
nofollow
external text
//www.worldcat.org/issn/1097-4172

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/26687358

values:
nofollow
external text
//doi.org/10.1093%2Fnar%2Fgkn076

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/18299284

values:
nofollow
external text
//doi.org/10.1186%2F1742-4690-6-18

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/19220914

values:
nofollow
external text
//doi.org/10.1515%2Fhsz-2013-0165

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/23787464

values:
nofollow
external text
//doi.org/10.1038%2F350508a0

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/2014052

values:
nofollow
external text
//doi.org/10.1038%2Fnm0396-338

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/8612235

values:
nofollow
external text
//doi.org/10.1073%2Fpnas.221256498

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/11593029

values:
nofollow
external text
//doi.org/10.1038%2F34571

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/9440686

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/15647694

values:
nofollow
external text
//doi.org/10.1038%2F381661a0

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/8649511

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/8629022

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/2152500

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/15080180

values:
nofollow
external text
//doi.org/10.1126%2Fscience.8356453

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/8356453

values:
nofollow
external text
//doi.org/10.1172%2FJCI117560

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/7962552

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/8627789

values:
nofollow
external text
//doi.org/10.1089%2Faid.2005.21.371

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/15929699

values:
nofollow
external text
//doi.org/10.1126%2Fscience.276.5309.51

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/9122710

values:
nofollow
external text
//doi.org/10.1093%2Finfdis%2F170.6.1367

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/7995974

values:
nofollow
external text
//doi.org/10.1093%2Finfdis%2F173.2.349

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/8568295

values: This citation requires a reference to the specific page or range of pages in which the material appears. (December 2017)

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/9630213

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/9632381

values:
nofollow
external text
//doi.org/10.1038%2Fni1566

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/18264102

values:
nofollow
external text
//doi.org/10.1038%2Fnm0703-847

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/12835704

values:
nofollow
external text
//doi.org/10.1073%2Fpnas.0900502106

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/19667186

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/15650184

values:
nofollow
external text
//doi.org/10.1016%2Fj.cell.2009.02.046

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/19410541

values:
nofollow
external text
//doi.org/10.1186%2F1742-4690-6-84

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/19765276

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/20446005

values:
nofollow
external text
//doi.org/10.1016%2Fj.tim.2010.09.003

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/20965729

values:
nofollow
external text
//doi.org/10.1016%2Fj.imlet.2004.11.026

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/15752562

values:
nofollow
external text
//doi.org/10.1172%2FJCI11918

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/11160127

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/9891806

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/11884533

values:
nofollow
external text
//doi.org/10.3390%2Fv8070192

values:
nofollow
external text
//www.worldcat.org/issn/1999-4915

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/27428992

values:
nofollow
external text
//doi.org/10.1261%2Frna.813608

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/18495939

values:
nofollow
external text
//doi.org/10.1126%2Fscience.1700865

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/1700865

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/16474154

values:
nofollow
external text
//doi.org/10.1128%2FJVI.00083-07

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/17494080

values:
nofollow
external text
//doi.org/10.1128%2FJVI.00936-06

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/16973569

values:
nofollow
external text
//doi.org/10.1126%2Fscience.1101786

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/15567861

values:
nofollow
external text
//doi.org/10.1007%2Fs000180050106

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/9447238

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/18295550

values:
nofollow
external text
//doi.org/10.1038%2F360358a0

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/1360148

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/25837979

values:
nofollow
external text
//doi.org/10.1084%2Fjem.20030648

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/14734528

values:
nofollow
external text
//doi.org/10.1038%2Fnrmicro1972

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/18923409

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/24005480

values:
nofollow
external text
//doi.org/10.1038%2Fncomms2338

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/23271654

values:
nofollow
external text
//doi.org/10.1038%2Fnature10347

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/21849975

values:
nofollow
external text
//doi.org/10.1007%2FBF00163230

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/7723052

values:
nofollow
external text
//doi.org/10.1038%2Fnrg1246

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/14708016

values:
nofollow
external text
//doi.org/10.1002%2Fsim.3116

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/17960579

values:
nofollow
external text
//doi.org/10.1038%2Fnm.2013

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/19661993

values:
nofollow
external text
//doi.org/10.1006%2Fviro.2001.0870

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/11336557

values:
nofollow
external text
//doi.org/10.1073%2Fpnas.88.18.8126

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/1896460

values:
nofollow
external text
//doi.org/10.1126%2Fscience.6695172

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/6695172

values:
nofollow
external text
//doi.org/10.1038%2Fnature08200

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/19626114

values:
nofollow
external text
//doi.org/10.1016%2Fj.cell.2006.04.033

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/16777597

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/12150845

values: Category:CS1 maint: Uses authors parameter

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/11832690

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/12505029

values:
nofollow
external text
//doi.org/10.1038%2Fnm.2016

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/19648927

values:
nofollow
external text
//doi.org/10.1126%2Fscience.1126531

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/16728595

values:
nofollow
external text
//doi.org/10.1002%2Fjid.797

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/11718472

values:
nofollow
external text
//doi.org/10.1093%2Finfdis%2F164.4.656

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/1894929

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/15998755

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/20642270

values:
nofollow
external text
//doi.org/10.1016%2Fj.cell.2016.05.024

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/27315479

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/19381076

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/18657710

values:
nofollow
external text
//doi.org/10.1056%2FNEJMoa1105243

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/21767103

values:
nofollow
external text
//doi.org/10.2105%2FAJPH.96.6.980

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/16714472

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/7287964

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/6116083

values:
nofollow
external text
//doi.org/10.1096%2Ffj.07-8697rev

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/17639073

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/6808340

values:
nofollow
external text
//doi.org/10.1126%2Fscience.6189183

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/6189183

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/6811853

values: American Association for the Advancement of Science

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/6815471

values:
nofollow
external text
//doi.org/10.1126%2Fscience.6601823

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/6601823

values:
nofollow
external text
//doi.org/10.1126%2Fscience.6206563

values: Category:CS1 maint: Explicit use of et al.

values: Category:CS1 maint: Multiple names: authors list

values:
nofollow
external text
//doi.org/10.1101%2Fcshperspect.a006841

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/22229120

values:
nofollow
external text
//doi.org/10.1126%2Fscience.1256739

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/25278604

values:
nofollow
external text
//doi.org/10.1038%2F17130

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/9989410

values:
nofollow
external text
//doi.org/10.1016%2Fj.cell.2008.09.022

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/18854152

values:
nofollow
external text
//doi.org/10.1098%2Frstb.2001.0863

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/11405934

values:
nofollow
external text
//doi.org/10.3201%2Feid1112.050394

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/16485481

values:
nofollow
external text
//doi.org/10.1098%2Frstb.2001.0867

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/11405938

values:
nofollow
external text
//doi.org/10.1038%2Fnature07390

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/18833279

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/20376191

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/10628811

values:
/wiki/Donald_McNeil,_Jr.
mw-redirect
Donald McNeil, Jr.

values:
nofollow
external text
//doi.org/10.1038%2F35400

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/9468138

values: -moz-column-width: 32em; -webkit-column-width: 32em; column-width: 32em; list-style-type: decimal;

values:
nofollow
external text
//doi.org/10.1002%2Fjmv.20478

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/16254974

values:
nofollow
external text
//doi.org/10.1096%2Ffj.05-3962fje

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/16174786

values: padding-bottom: 0.75em; text-align: center;

attrs: alt src width height style srcset data-file-width data-file-height

values: display: inline-block; width: 31px; line-height: 31px; vertical-align: middle; text-align: center;

values: display: inline-block; margin-left: 4px; width: 182px; vertical-align: middle;

values: b:Sexual Health/Sexually Transmitted Diseases

values: border-top:1px solid #aaa; padding-top: 0.75em;

values: metadata plainlinks plainlist mbox-small

values: border:1px solid #aaa; padding:0.75em; background:#f9f9f9;

values: CDC classification system for HIV infection

values: WHO disease staging system for HIV infection and disease

values: WHO Disease Staging System for HIV Infection and Disease in Children

values: WHO Disease Staging System for HIV Infection and Disease in Adults and Adolescents

values: List of countries by HIV/AIDS adult prevalence rate

values: Diffuse infiltrative lymphocytosis syndrome

values:
/wiki/AIDS_Museum
mw-redirect
AIDS Museum

values: Discrimination against people with HIV/AIDS

values:
/wiki/International_AIDS_Conference
mw-redirect
International AIDS Conference

values: President's Emergency Plan for AIDS Relief

values: nowraplinks collapsible autocollapse navbox-subgroup

values:
/wiki/AIDS_pandemic
mw-redirect
AIDS pandemic

values: HIV/AIDS in the Democratic Republic of the Congo

values: List of HIV/AIDS cases and deaths registered by region

values: nowraplinks hlist collapsible autocollapse navbox-inner

values: ICD-10 Chapter I: Certain infectious and parasitic diseases

values: List of ICD-9 codes 001–139: infectious and parasitic diseases

values:
/wiki/Ureaplasma_infection
mw-redirect
Ureaplasma infection

values:
/wiki/Human_papillomavirus
mw-redirect
Human papillomavirus

values: nowraplinks collapsible autocollapse navbox-inner

values: Xenotropic murine leukemia virus-related virus

values:
/wiki/Cellular_reprogramming
mw-redirect
Cellular reprogramming

values: First observation of gravitational waves

values:
nofollow
external text
https://d-nb.info/gnd/4200792-6

values:
nofollow
external text
https://www.idref.fr/028936868

values: Category:Discovery and invention controversies

values: Category:Sexually transmitted diseases and infections

values: Category:Wikipedia articles needing page number citations from December 2017

values: Category:Wikipedia indefinitely semi-protected pages

values: Category:Articles with 'species' microformats

values: Category:All articles with failed verification

values: Category:Articles with failed verification from April 2014

values: Category:All articles with unsourced statements

values: Category:Articles with unsourced statements from February 2015

values: Category:Articles with unsourced statements from November 2014

values: Category:Wikipedia articles in need of updating from January 2013

values: Category:All Wikipedia articles in need of updating

values: Category:Wikipedia articles with LCCN identifiers

values: Category:Wikipedia articles with GND identifiers

values: Category:Wikipedia articles with BNF identifiers

values: Discussion about edits from this IP address [ctrl-alt-n]

values: A list of edits made from this IP address [ctrl-alt-y]

values: You are encouraged to create an account and log in; however, it is not mandatory

values: You're encouraged to log in; however, it's not mandatory. [ctrl-alt-o]

values:
/wiki/HIV
View the content page [ctrl-alt-c]
c

values: Discussion about the content page [ctrl-alt-t]

values: p-namespaces navigation vectorTabs p-namespaces-label

values:
p-variants
navigation
vectorMenu emptyPortlet
p-variants-label

values:
This page is protected.
You can view its source [ctrl-alt-e]

values: Past revisions of this page [ctrl-alt-h]

values: p-views navigation vectorTabs p-views-label

values:
p-cactions
navigation
vectorMenu emptyPortlet
p-cactions-label

values:
mw-wiki-logo
/wiki/Main_Page
Visit the main page

values:
/wiki/Main_Page
Visit the main page [ctrl-alt-z]
z

values: Featured content – the best of Wikipedia

values: Find background information on current events

values:
/wiki/Special:Random
Load a random article [ctrl-alt-x]
x

values: portal navigation p-navigation p-navigation-label

values: Guidance on how to use and edit Wikipedia

values: About the project, what you can do, where to find things

values: A list of recent changes in the wiki [ctrl-alt-r]

values: portal navigation p-interaction p-interaction-label

values: List of all English Wikipedia pages containing links to this page [ctrl-alt-j]

values: Recent changes in pages linked from this page [ctrl-alt-k]

values:
/wiki/Wikipedia:File_Upload_Wizard
Upload files [ctrl-alt-u]
u

values: A list of all special pages [ctrl-alt-q]

values: Permanent link to this revision of the page

values: Link to connected data repository item [ctrl-alt-g]

values: Printable version of this page [ctrl-alt-p]

values: portal navigation p-wikibase-otherprojects p-wikibase-otherprojects-label

values:
https://af.wikipedia.org/wiki/MIV
MIV – Afrikaans
af
af
interlanguage-link-target

values:
https://als.wikipedia.org/wiki/HIV
HIV – Alemannisch
als
als
interlanguage-link-target

values: فيروس العوز المناعي البشري – Arabic

values: Virus de la inmunodeficiencia humana – Asturian

values: İnsanın immunçatışmazlığı virusu – Azerbaijani

values: এইচআইভি – Bangla

values: Вірус імунадэфіцыту чалавека – Belarusian

values: interlanguage-link interwiki-be badge-Q17437798 badge-goodarticle

values: ВІЧ – Belarusian (Taraškievica orthography)

values:
https://bs.wikipedia.org/wiki/HIV
HIV – Bosnian
bs
bs
interlanguage-link-target

values: Хүнэй дархалал хомсодолой вирус – Russia Buriat

values: Virus de la immunodeficiència humana – Catalan

values:
https://cs.wikipedia.org/wiki/HIV
HIV – Czech
cs
cs
interlanguage-link-target

values:
https://cy.wikipedia.org/wiki/HIV
HIV – Welsh
cy
cy
interlanguage-link-target

values: interlanguage-link interwiki-da badge-Q17559452 badge-recommendedarticle

values:
https://de.wikipedia.org/wiki/HIV
HIV – German
de
de
interlanguage-link-target

values: interlanguage-link interwiki-de badge-Q17437798 badge-goodarticle

values:
https://et.wikipedia.org/wiki/HIV
HIV – Estonian
et
et
interlanguage-link-target

values: Ιός ανθρώπινης ανοσοανεπάρκειας – Greek

values: Virus de la inmunodeficiencia humana – Spanish

values:
https://eo.wikipedia.org/wiki/HIV
HIV – Esperanto
eo
eo
interlanguage-link-target

values: interlanguage-link interwiki-eu badge-Q17437796 badge-featuredarticle

values: اچ‌آی‌وی – Persian

values: Virus de l'immunodéficience humaine – French

values:
https://fy.wikipedia.org/wiki/HIV
HIV – Western Frisian
fy
fy
interlanguage-link-target

values: Víreas easpa imdhíonachta daonna – Irish

values: Virus da inmunodeficiencia humana – Galician

values: 인간면역결핍 바이러스 – Korean

values:
https://hr.wikipedia.org/wiki/HIV
HIV – Croatian
hr
hr
interlanguage-link-target

values:
https://ilo.wikipedia.org/wiki/HIV
HIV – Iloko
ilo
ilo
interlanguage-link-target

values:
https://id.wikipedia.org/wiki/HIV
HIV – Indonesian
id
id
interlanguage-link-target

values:
https://is.wikipedia.org/wiki/HIV-veira
HIV-veira – Icelandic
is
is
interlanguage-link-target

values:
https://it.wikipedia.org/wiki/HIV
HIV – Italian
it
it
interlanguage-link-target

values:
https://he.wikipedia.org/wiki/HIV
HIV – Hebrew
he
he
interlanguage-link-target

values:
https://ku.wikipedia.org/wiki/Soy_HIV
Soy HIV – Kurdish
ku
ku
interlanguage-link-target

values: Адамдын иммунитет жетишсиздигинин вирусу – Kyrgyz

values:
https://la.wikipedia.org/wiki/VIDH
VIDH – Latin
la
la
interlanguage-link-target

values:
https://lv.wikipedia.org/wiki/HIV
HIV – Latvian
lv
lv
interlanguage-link-target

values:
https://lt.wikipedia.org/wiki/%C5%BDIV
ŽIV – Lithuanian
lt
lt
interlanguage-link-target

values:
https://hu.wikipedia.org/wiki/HIV
HIV – Hungarian
hu
hu
interlanguage-link-target

values:
https://ms.wikipedia.org/wiki/HIV
HIV – Malay
ms
ms
interlanguage-link-target

values:
https://nl.wikipedia.org/wiki/Hiv
Hiv – Dutch
nl
nl
interlanguage-link-target

values: एचआइभी – Nepali

values: ヒト免疫不全ウイルス – Japanese

values:
https://no.wikipedia.org/wiki/Hiv
Hiv – Norwegian
no
no
interlanguage-link-target

values: Virus de l'immunodeficiéncia umana – Occitan

values: ଏଚ.ଆଇ.ଭି. – Odia

values: اېچ آی وي – Pashto

values: Ludzki wirus niedoboru odporności – Polish

values: Vírus da imunodeficiência humana – Portuguese

values: interlanguage-link interwiki-pt badge-Q17437798 badge-goodarticle

values:
https://ro.wikipedia.org/wiki/HIV
HIV – Romanian
ro
ro
interlanguage-link-target

values: Вирус иммунодефицита человека – Russian

values: interlanguage-link interwiki-ru badge-Q17437798 badge-goodarticle

values:
https://sco.wikipedia.org/wiki/HIV
HIV – Scots
sco
sco
interlanguage-link-target

values:
https://sq.wikipedia.org/wiki/HIV
HIV – Albanian
sq
sq
interlanguage-link-target

values: මානව ප්‍රතිශක්ති ඌණතා වෛරසය – Sinhala

values:
https://simple.wikipedia.org/wiki/HIV
HIV – Simple English
simple
simple
interlanguage-link-target

values:
https://sk.wikipedia.org/wiki/HIV
HIV – Slovak
sk
sk
interlanguage-link-target

values:
https://sl.wikipedia.org/wiki/HIV
HIV – Slovenian
sl
sl
interlanguage-link-target

values: ڤایرۆسی نەمانی بەرگری لە مرۆڤ – Central Kurdish

values:
https://sh.wikipedia.org/wiki/HIV
HIV – Serbo-Croatian
sh
sh
interlanguage-link-target

values:
https://su.wikipedia.org/wiki/HIV
HIV – Sundanese
su
su
interlanguage-link-target

values:
https://fi.wikipedia.org/wiki/HIV
HIV – Finnish
fi
fi
interlanguage-link-target

values:
https://sv.wikipedia.org/wiki/HIV
HIV – Swedish
sv
sv
interlanguage-link-target

values:
https://tl.wikipedia.org/wiki/HIV
HIV – Tagalog
tl
tl
interlanguage-link-target

values: எச்.ஐ.வி – Tamil

values: เอชไอวี – Thai

values:
https://tr.wikipedia.org/wiki/HIV
HIV – Turkish
tr
tr
interlanguage-link-target

values:
https://tk.wikipedia.org/wiki/AIW
AIW – Turkmen
tk
tk
interlanguage-link-target

values: Вірус імунодефіциту людини – Ukrainian

values:
https://vi.wikipedia.org/wiki/HIV
HIV – Vietnamese
vi
vi
interlanguage-link-target

values:
https://fiu-vro.wikipedia.org/wiki/HIV
HIV – Võro
fiu-vro
fiu-vro
interlanguage-link-target

values:
https://war.wikipedia.org/wiki/HIV
HIV – Waray
war
war
interlanguage-link-target

values:
https://zh-yue.wikipedia.org/wiki/HIV
HIV – Cantonese
zh-yue
zh-yue
interlanguage-link-target

values:
https://diq.wikipedia.org/wiki/HIV
HIV – Zazaki
diq
diq
interlanguage-link-target

values: 人類免疫缺陷病毒 – Chinese

values: mediawiki ltr sitedir-ltr mw-hide-empty-elt ns-0 ns-subject page-HIV rootpage-HIV skin-vector action-view